

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cohort profile: Chinese elderly with multimorbidity in primary care in Hong Kong

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027279
Article Type:	Cohort profile
Date Submitted by the Author:	16-Oct-2018
Complete List of Authors:	Zhang, Dexing; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Sit, Regina Wing Shan; The Chinese University of Hong Kong, JC School of Public Health and Primary Care Wong, Carmen; The Chinese University of Hong Kong , Jockey Club School of Public Health and Primary Care Zou, Dan; The Chinese University of Hong Kong, JC School of Public Health and Primary Care Mercer, Stewart; University of Glasgow, Institute of Health and Wellbeing Johnston, Marjorie; University of Aberdeen, Wong, Samuel; Chinese University of Hong Kong, School of Public Health and Primary Care
Keywords:	Multimorbidity, Prospective Cohort , Older Adults, PRIMARY CARE, Physical, Psychological and Social Factors

SCHOLARONE™
Manuscripts

Cohort profile: Chinese elderly with multimorbidity in primary care in Hong Kong

Dexing Zhang,¹ Regina Wing Shan Sit,¹ Carmen Wong,¹ Dan Zou,¹ Stewart W. Mercer,² Marjorie Johnston,³ Samuel Yeung Shan Wong^{1*}

1. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR
2. The Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh, The United Kingdom
3. The Institute of Applied Health Sciences, University of Aberdeen, The United Kingdom

* Corresponding Author:

Name: Samuel Yeung Shan WONG

Email: yeungshanwong@cuhk.edu.hk

Tel: (852) 2252 8774

Fax: (852) 2606 3500

Address: 4/F, JC School of Public Health and Primary Care, Prince of Wales Hospital, Shatin, N.T., Hong Kong

Funding

The staff working on this cohort received funding from the Hong Kong Jockey Club Charities Trust.

Acknowledgements

We would like to thank the General Out-patient Clinics (Lek Yuen, Ma On Shan, Shatin (Tai Wai), Yuen Chau Kok) and Shatin Rhenish Neighbourhood Elderly Centre for the support and help in recruitment. We also greatly thank all the patients who joined in the cohort.

Patient consent Obtained

Ethics approval Compliance with Ethical Standards. Ethics approval was obtained from the Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee (The Joint CUHK-NTEC CREC).

Conflict of Interest None declared

Contributors SYSW conceived and supervised the study and revised the manuscript. DXZ contributed to study design, analysed the data, prepared the draft and revised the manuscript. SRWS and CW contributed to the study design and implementation, and manuscript revisions. DZ contributed in data collection and manuscript revisions. SWM and MJ contributed in manuscript revisions.

Cohort Registration ChiCTR-OIC-16008477

Word count: 3330 words (excluding abstract, references, tables and figures)

Abstract

Purpose

This cohort aims to examine health profile of primary care patients with multimorbidity longitudinally, and the potential impact of multimorbidity on health service utilization, quality of life and mortality among elderly patients in primary care in Hong Kong. This paper aims to describe the cohort design and baseline characteristics.

Participants

A total of 1080 patients aged 60 years or above with at least two chronic diseases were recruited in 4 public primary care clinics in the New Territories East Region of Hong Kong.

Findings to date

The study sample comprised 70% women with a mean age of 70.0 years (SD=6.8); 61% were overweight or obese; the mean number of chronic conditions was 4.1 (1.8); the mean medication in use was 2.4 (1.9); more than 70% rated their health as fair or poor; 18% were frail; three quarters reported the presence of one (11%) or two or more (64%) body pain areas; 12% had mild cognitive impairment; 19% had mild depression or above; 16% had mild anxiety or above; 49% had insomnia at sub-threshold level or above; 28% indicated being lonely; the EQ-5D-5L index score was -0.6 (0.2) and its visual analogue scale (VAS) score was 67.0 (14.8) out of 100; in the past 12 months, 17% admitted to hospital, 91% attended general out-patient clinic (GOPC), 70% attended specialist out-patient clinic (SOPC), and 10% used elderly day care center services; and the median out-of-pocket health cost was 1000 HK\$ (US\$150).

Future plans

Future plans will be longitudinally studying health profiles of patients with multimorbidity, the longitudinal association of psychosocial factors and multimorbidity, as well as influence of multimorbidity on quality of life and mortality. Health service utilization in primary and secondary care will also be studied.

Key Words:

Multimorbidity; Prospective Cohort; Older Adults; Primary Care; Physical, Psychological and Social Factors

Strengths and limitations of this study

- This cohort specifically looks into the health profile of Hong Kong Chinese elderly with multimorbidity in primary care. As far as we are aware, very few prospective cohorts specifically cover this population in primary care, and no such cohort among Chinese.
- The study includes questionnaires and physical health assessments to identify physical and psychosocial problems commonly encountered in the elderly. The data are linked with health electronic records which allow follow up and examination of long-term outcomes associated with multimorbidity.
- The limitation was that older adult patients who were disabled, very ill, institutionalized, or home-bounded were unlikely to have been included in this study.

INTRODUCTION

Multimorbidity, defined as patients living with two or more chronic health conditions, is common in primary care. The prevalence is increasing over the last decades as a result of an aging population and changes in lifestyles e.g. more sedentary lifestyle.^{1 2} A recent systematic review suggests that the prevalence of multimorbidity is high among the elderly.³ Increasing age, being female and having a lower socioeconomic status are positively associated with multimorbidity.^{3 4} Multimorbidity is associated with increased disability and depression, reduced quality of life, and higher rates of adverse drug consequences. Multimorbidity leads to increased primary and secondary health service utilization, especially unplanned health care, as well as reduced life-expectancy.⁵

The management of multimorbidity is challenging to healthcare systems globally due to its heavy disease burden in multiple aspects. The common problems experienced by patients with multimorbidity include fragmentation and poor coordination of care, polypharmacy, treatment burden, mental health problems, functional disability, and increased healthcare expenditures.^{6 7} The direct and indirect economic burden associated with multimorbidity is huge.⁸ The annual healthcare costs were €4,096.86 among patients with 5 or more chronic conditions, which was almost 5 times more than those who were healthy in a study in the West of Ireland.⁹ The economic burden highlights an urgent need to search for cost-effective ways to manage patients with multimorbidity, given that treatment of diseases in isolation can be inefficient, leading to duplication of care and poorer health outcomes.¹⁰

Studies on multimorbidity have increased in recent years; however, important knowledge gaps still exist.¹¹ Although a guideline on clinical assessment and management of multimorbidity was developed by the NICE in 2016,¹² questions on the epidemiology and profiles of patients with multimorbidity to inform policy making are unanswered.^{3 13} For example, there is insufficient information on clustering of different conditions and limited research has been conducted on physical, psychological and social factors longitudinally associated with chronic conditions. In addition, the impact of multimorbidity on various patient outcomes such as loneliness, fatigue, use of different kinds of healthcare services is less studied.^{3 12-15} Therefore, cohort studies with multiple repeat measures of both exposures and outcomes are needed to advance our understanding of potential causality.^{14 16-20}

1
2
3 In Hong Kong, although there is a large private primary care sector, around 85% of people
4 with chronic conditions are managed in the public primary care setting. Given that Hong Kong
5 people have the longest life expectancy in the world: (81.7 for men and 87.7 for women in 2017),²¹
6 the ageing population and multimorbidity have brought much burden and challenge to the local
7 healthcare system. The present cohort aims to study the health profiles of patients with
8 multimorbidity who present to primary care in Hong Kong. The specific objectives are to examine:
9 1) health profiles of elderly patients in primary care; 2) the longitudinal association between
10 psychosocial factors and multimorbidity; and 3) the potential impact of multimorbidity on
11 healthcare utilization, quality of life and mortality. The findings of this study will inform
12 healthcare providers and policymakers in providing suitable health services for people with
13 multimorbidity in primary care. This paper aims to introduce the cohort methods and baseline
14 measures and results, with comparisons to two other population-based studies on the older adults
15 with two or more chronic conditions in Hong Kong.
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **COHORT DESCRIPTION**

30 **Study setting and participants**

31 Hong Kong has a population of 7.34 million according to the 2016 census data,²² with 23.7% aged
32 60 years or above, which was higher than the rates of 16.5% and 19.5% in 2006 and 2011,
33 respectively. This cohort contains primary care patients from four general out-patient clinics
34 (GOPCs) (Lek Yuen, Ma On Shan, Shatin (Tai Wai) and Yuen Chau Kok), which were available
35 as indicated by administrative staffs for patient recruitment during the study period, out of the ten
36 general out-patient clinics (GOPCs) in the New Territory East Cluster (NTEC), Hong Kong. Each
37 GOPC sees about 450 patients each day. The working hours are generally from 9:00 am to 5:00
38 pm from Monday to Friday with some additional night and weekend sessions. In the most recent
39 Hospital Authority Annual Report 2016-2017, the ten GOPCs in NTEC provided 972,454
40 consultations in total in the year of 2015/2016, which consisted of one third of total GOPC
41 consultations in Hong Kong public health system.²³
42
43
44
45
46
47
48
49
50

51 The inclusion criteria of participants were: 1) aged 60 years or above; 2) with two or more
52 chronic diseases confirmed by physicians; and 3) could speak and understand Chinese. No specific
53 exclusion criteria were adopted. However, as participants need to respond to questionnaire surveys
54
55
56
57

1
2
3 and health checks, they required to be able to access the clinic, sign informed consent by
4 themselves, and understand and answer the research questions.
5

6
7 Patients were first consecutively screened for eligibility by trained research assistants in
8 the out-patient waiting areas of the GOPCs. For those who were eligible, they were asked to
9 provide a contact phone number and then be scheduled to visit the study nurse for further
10 assessments. From April 2016 to October 2017, 1080 eligible patients were recruited and
11 completed the baseline assessments. All patients provided informed consent before participation
12 in the study. The flowchart of recruitment is shown in **Figure 1**. The baseline assessments were
13 conducted through face-to-face interviews by nurses or a social worker at a university affiliated
14 primary care clinic.
15
16
17
18
19
20
21

22 **Measures**

23
24 The assessments covered a range of measures that are postulated to be potential physical,
25 psychological and social factors associated with multimorbidity. All the measures were validated
26 and have been widely used or have been used in our previous studies. Information was collected
27 through face-to-face interviews by trained nurses and social workers, and additional information
28 of the disease entities, medication use and health service utilization were confirmed through the
29 review of electronic medical records by nurses. Each complete assessment lasted for about 45 to
30 60 minutes.
31
32
33
34
35

36 The measures in the questionnaires included: 1) the number and type of chronic diseases
37 in fifteen categories (a total of 43 chronic conditions); 2) depression (screened by the 2-item Patient
38 Health Questionnaire (PHQ-2)²⁴ and those with a score of 3 or more which suggests depression
39 were further measured by the 9-item Patient Health Questionnaire (PHQ-9);²⁵ 3) anxiety (screened
40 by the 2-item Generalised Anxiety Disorder (GAD-2) and those with a score of 3 or more which
41 suggests anxiety were further measured by the 7-item Generalised Anxiety Disorder (GAD-7);²⁶
42 4) loneliness (measured by the 6-item De Jong Gierveld Loneliness Scale,²⁷ as well as one
43 loneliness question; 5) insomnia (measured by the 7-item Insomnia Severity Index (ISI)²⁸ among
44 those who answered yes to the screening question); 6) pain (measured by the Brief Pain Inventory
45 among those who were screened positive in pain); 7) physical activity (measured by Physical
46 Activity Scale for the Elderly (PASE)²⁹ among those who were screened positive in pain); 8) frailty
47 (measured by the Edmonton Frail Scale³⁰ which was translated and back-translated by experienced
48
49
50
51
52
53
54
55
56
57

1
2
3 bilingual translators); 9) meaning of existence (measured by one question extracted from the
4 validated Chinese Purpose in Life test (CPIL) which was used in a previous study);³¹ 10)
5 sarcopenia (measured by the 5-item Sarcopenia Assessment (SARC-F)^{32 33}; 11) cognition
6 (measured by the Hong Kong Montreal Cognitive Assessment (HK-MoCA) with a score of 22 or
7 above being with normal cognition);³⁴ 12) alcohol use (screened by one question and then
8 measured by the 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C) for
9 those who screened positive); 13) smoking (non-smoker, current smoker, ex-smoker); 14)
10 medication use (number and duration (0-1 year/2-5 years/>5 years) of antihypertensive,
11 cardiovascular and hypolipidemic drugs, antidiabetics, antipsychotics and analgesics was checked
12 in electronic medical system, and compliance of medication use was measured by “At times, do
13 you forget to take your prescription medications?” (no/yes)); 15) self-rated health; 16) community
14 network; 17) use of social media (measured by a screening question, and for those who answered
15 yes to any of the social media, they were further assessed with importance and comfort of using
16 internet); 17) oral health; 18) incontinence; 19) caregiving to somebody; 20) quality of life was
17 measured by the EuroQol EQ-5D-5L (EQ5D);³⁵ 21) daily function (ability to use telephone, mode
18 of transportation, shopping, food preparation, ability to handle finances were measured); 22) health
19 service utilization was recorded by visits to primary care doctors, specialist outpatient clinics,
20 admission to hospital, use of services in elderly daycare centers and out-of-pocket healthcare cost
21 which was not covered by public health system or insurance both in private and public in the past
22 year. In addition, physical examinations included blood pressure, weight, height and Body Mass
23 Index (BMI), waist circumference and handgrip strength (kg). Social economical status such as
24 age, gender, marriage, living status, employment, receiving of social welfare scheme was also
25 included. Due to a change of data collection plan, some measures were only collected among part
26 of the patients in a later stage. Summaries of the measures at baseline are described in **Table 1**.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The questionnaire was set up in password protected EpiData files in a password protected
computer with quality control, e.g., for scale question with answers of a Likert scale of 1 to 5, a
range of 1-5 and one digit was set up so no other results were allowed during data entry; and for
most data variables, a must enter was set up, so that it could not be missed unless answered or
purposely move to next question. Checking for missing data was done regularly by experienced
researchers and missing data was further collected by nurses through face-to-face interviews,
telephone or by checking of the electronic medical record system.

Patient and Public Involvement

The research questions and outcome measures were developed based on some most common problems that are widely recognized among elder patients. Patients or the public did not involve in the design of the study, recruitment or conduction of the study. The results of the study would be disseminated to patients once he or she requests so and aggregated data would be reported in project reports and research publications.

Findings to date

Baseline characteristics of the patients in the cohort are shown in **Table 2**. The mean age of patients was 70 (SD=6.8) years with 70% being females, 67% married, 14% living alone, 92% retired or housewives, 49% had 6 years of education or above, 10% on Comprehensive Social Security Assistance (CSSA) scheme, about half used social media in last 2 weeks, and about 18% provided care to another one such as their spouse or children/grandchildren; the mean BMI was 24.2 (SD=3.6): 61% were overweight or obese; 12% had ever drunk alcohol in the past year and 3% were current smoker.

Overall, the mean number of chronic diseases was 4.1 (SD=1.8) and about one in five of patients had 6 or more chronic diseases. The top three chronic conditions were hypertension (73%), dyslipidemia (46%), and skeletal and connective tissue inflammation (e.g. arthritis) (37%). The prevalence of co-morbidities of the 15 disease categories among the patients is shown in **Figure 2**. The most prevalent co-morbidities out of the 43 specific chronic conditions under the 15 categories are shown in **Figure 3**, with the combination of hypertension and dyslipidemia being the most common (38% of the patients), followed by hypertension and skeletal and connective tissue inflammation (e.g. arthritis) (27%), hypertension and diabetes mellitus (26%), chronic pain and diabetes mellitus (21%), and hypertension and chronic pain (19%). On average, patients took 2.4 (SD=1.9) medications, with 27% taking 5 or more medications regularly.

There were 17.5% frail based on Edmonton Frail Scale. Eight percent had sarcopenia, 24% reported chewing difficulty, 20% reported incontinence, 35% had stage one or two hypertension according to the physical check, the average handgrip strength (best outcomes of the two trials of both hands) were 21.9 (SD=6.7) kg; 10% needed help or being dependent in at least one out of the 5 daily functions (using telephone, transportation, shopping, preparing meals, or financial

1
2
3 management). Overall, 28%, 59% and 12% of patients rated their health being ‘excellent/very
4 good/good’, ‘fair’, or ‘poor’ respectively. Seventy-five percent reported the presence of one (11%)
5 or two or more (64%) body pain areas, 12% scored the HK-MoCA <22 suggesting at least mild
6 cognitive impairment, 19% had PHQ-2 ≥ 3 and 19% had PHQ-9 ≥ 5 suggesting mild depression or
7 above, 17% had GAD-2 ≥ 3 and 16% had GAD-7 ≥ 5 suggesting mild anxiety or above, 28%
8 reported feeling lonely, 49% had insomnia at subthreshold level or above, the mean score of
9 meaning of existence was 4.8 (SD=1.2) out of 7; the EQ-5D-5L index score was -0.6 (0.2) and its
10 visual analogue scale (VAS) score was 67.0 (14.8) out of 100.
11
12

13
14
15
16
17 Seventeen percent were admitted to hospital in the previous year, 91% attended GOPC,
18 70% attended SOPC, 10% used elderly day care center services and the median out-of-pocket
19 health cost was 1000 HK\$ (US\$150) for any health expenditures not covered by the public health
20 system or insurance. Details of the findings can be seen in **Table 2**.
21
22
23
24

25 **Comparison of participant characteristics with two other population-based surveys**

26
27 Comparison was made with the data from the two population-based surveys: the Elderly Telephone
28 Survey (ETS) and Thematic Household Survey (THS) 2011 with participants age ≥ 60 and having
29 two or more chronic diseases in these two surveys included. The Elderly Telephone Survey was a
30 population-based survey conducted in 2016 on older adults aged 60 or above. The ETS was a
31 random population-based telephone survey on 1000 older adults who could speak Cantonese in
32 the households.³⁶ It included items focusing on primary care, health service utilization, and access
33 to care were extracted from the 2014 Commonwealth Fund International Health Policy Survey of
34 Older Adults. In ETS, 414 people aged 60 or above had two or more chronic conditions. The THS
35 was a population-based household survey which collected data on different social and health topics
36 since 1999. The data used for comparison in this study was collected from October 2011 to January
37 2012.³⁷ This THS included topics on health and healthcare utilization besides socio-demographic
38 data on 10,065 out of a total of 13,411 sampled households with a response rate of 75% using
39 face to face interviews. In total, 29,187 persons were interviewed. The survey did not include
40 institutionalized residents, persons living on board vessels, foreign domestic helpers and hotel
41 transients. It included 2301 people aged 60 or above with two or more chronic conditions.
42
43
44
45
46
47
48
49
50
51
52

53 The available data for comparisons between the current cohort and the two surveys are
54 shown in Table 2. Chi-square tests were used for comparisons. It shows that the current cohort has
55
56
57

1
2
3 more females, relatively younger age, higher education level, fewer recipients of social security
4 schemes, more chronic conditions, relatively better self-rated health, less smokers, and more out-
5 patient clinic visits in the past year, while their marital, employment status, and number of
6 hospitalisation in the past year were similar.
7
8
9

10 11 12 **Follow-up**

13 The patients will be followed-up regularly (interval of 2 years) to monitor changes in health status
14 and outcomes by both questionnaire and physical assessments. The first follow-up (i.e., wave 2
15 assessment) started in early 2018. Additional information on mobility by the 30 second chair-stand
16 test, visual acuity by Amsler Grid test and hearing by Weber's test and Rinne Test were added.
17 Information on electronic medical records will also be updated to provide information on health
18 outcomes including health service utilization, changes in medication use, and new onset of diseases
19 and death.
20
21
22
23
24
25
26

27 28 **Analysis plan**

29 Based on the cohort aims, the analyses will include the following: 1) Longitudinal biopsychosocial
30 health profiles of primary care patients with multimorbidity: 2) longitudinal association of
31 multimorbidity (or common diseases or common disease combinations) and psychosocial factors
32 such as pain, sarcopenia, cognition, depression, anxiety, insomnia, meaning of existence,
33 loneliness and social network; 3) the longitudinal impact of multimorbidity on healthcare use,
34 quality of life and mortality. In addition, further analyses would include but not limit to
35 polypharmacy (health conditions and factors associated with polypharmacy); and associated
36 factors of quality of life, mortality or a specific problem over time such as depression, anxiety,
37 insomnia, loneliness, perceived meaning of existence, self-rated health, frailty, pain, sarcopenia,
38 cognitive impairment, incontinence, oral health, social support.
39
40
41
42
43
44
45
46
47

48 49 **Discussion**

50 This is one of the few etiological cohorts on older adults being conducted in Asian primary care
51 settings to examine physical, psychological and social factors associated with multimorbidity. It
52 has been estimated that by 2030, 66% of the global disease burden will be due to non-
53 communicable disease, with most of the burden occurring in the most populous area – Asia.^{38 39}
54
55
56
57

1
2
3 Previous studies⁴⁰⁻⁴³ examined factors associated with multimorbidity in primary care and found
4 that poor mental well-being (depression, anxiety, insomnia, loneliness) were associated with the
5 presence of multimorbidity and it was also found that depression, anxiety, insomnia and loneliness
6 was also prevalent as shown in our findings.
7
8
9

10 In the present study, we found that those who suffered from multimorbidity had the
11 psychological problems are common, including more than 10% suffering from mild cognitive
12 impairment, more than half suffering from chronic physical pain involving two body parts and
13 with almost 20% with either depressive or anxiety symptoms. Moreover, sleep disturbance appears
14 to be common with almost half being assessed reported significant sleep related symptoms.
15
16
17

18 It is well established that people with multimorbidity have reduced quality of life. Previous
19 studies⁴⁴⁻⁴⁶ showed that people with multimorbidity have significantly reduced quality of life. In
20 the current cohort, the majority of patients rated their quality of life as being low comparing to the
21 general public.³⁵ Self-reported quality of life has been shown to be a good predictor of mortality.⁴⁷
22 Our findings suggest that people with multimorbidity have complex health needs in physical,
23 mental and social aspects such as multiple body pain, depression, anxiety, insomnia and loneliness.
24
25
26
27
28

29 We show that in addition to their physical chronic conditions, older adults with
30 multimorbidity are also affected by significant psychological and social problems. A holistic
31 approach that addresses general physical and functional domain of health, at the same time
32 assessing and managing psychological and social problems may be needed to look after older
33 adults with multimorbidity.
34
35
36
37
38

39 **Strengths and Limitations**

40
41 This cohort has several strengths. First, it covers a lot of biopsychosocial factors which are not
42 included in other previous large-scale cohorts only with extracted medical or insurance records.
43 Second, the sample size is relatively large allowing exploration of associated factors and changes
44 in common health problems among elderly populations with multimorbidity. Third, this is one of
45 the very few cohorts based on primary care patients with multimorbidity and to our knowledge is
46 a unique one among Chinese populations. Fourth, as this is relatively stable cohort, it will allow
47 us to follow-up them in the very long term with the support from doctors and nurses, as well as the
48 use of clinical management system information.
49
50
51
52
53
54
55
56
57

1
2
3 Since only those who agreed to participate in the current study were recruited, the limitation
4 is that the prevalence of various health issues may not be representative of the general older adult
5 population with multimorbidity. However, we have compared the demographics of this cohort to
6 those of the older adults in two population-based surveys and found that the distribution of age,
7 socio-economic status and lifestyle factors such as smoking suggesting that people in the current
8 cohort were more females, younger, with higher education level, higher social status, more number
9 of chronic conditions, relatively better self-rated health and less smokers, which might be a result
10 of voluntary participation in the study. The sample size may then have been too small to examine
11 factors associated with multimorbidity in some subgroups such as older men and people with lower
12 educational levels. Second, only ambulatory adults were included in this study and our findings
13 are therefore only be applicable in ambulatory old adults in primary care.
14
15
16
17
18
19
20
21
22
23

24 **Collaboration**

25 The authors warmly welcome collaborations. For those who would like to request for the data or
26 propose new assessments into the follow-up assessments, they can email to:
27 [yeungshanwong@cuhk.edu.hk]. For more information please see the website:
28 [29 http://cpcp.sphpc.cuhk.edu.hk/chi/](http://cpcp.sphpc.cuhk.edu.hk/chi/).
30
31
32
33
34
35

36 **Reference**

- 37 1. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the
38 last 20 years. *The European journal of general practice* 2008;14 Suppl 1:28-32. doi:
39 10.1080/13814780802436093 [published Online First: 2008/10/31]
- 40 2. Pefoyo AJ, Bronskill SE, Gruneir A, et al. The increasing burden and complexity of
41 multimorbidity. *BMC public health* 2015;15:415. doi: 10.1186/s12889-015-1733-2
42 [published Online First: 2015/04/24]
- 43 3. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of
44 multimorbidity in primary care: A systematic review of observational studies: PLoS
45 ONE. 9 (7) , 2014. Article Number: e102149. Date of Publication: 21 Jul 2014. 2014.
- 46 4. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the
47 last 20 years. *Eur J Gen Pract* 2008;14 Suppl 1:28-32. doi: 10.1080/13814780802436093
48 [published Online First: 2008/10/31]
- 49 5. Salisbury C. Multimorbidity: Time for action rather than words: *British Journal of General*
50 *Practice*. 63 (607) (pp 64-65), 2013. Date of Publication: February 2013. 2013.
- 51 6. Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary
52 care. *Bmj* 2015;350:h176. doi: 10.1136/bmj.h176 [published Online First: 2015/02/04]
53
54
55
56
57

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
7. Gill A, Kuluski K, Jaakkimainen L, et al. "Where do we go from here?" Health system frustrations expressed by patients with multimorbidity, their caregivers and family physicians: *Healthcare Policy*. 9 (4) (pp 73-89), 2014. Date of Publication: May 2014. 2014.
8. Picco L, Achilla E, Abdin E, et al. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. *Bmc Health Serv Res* 2016;16 doi: Artn 17310.1186/S12913-016-1421-7
9. Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. *Family practice* 2011;28(5):516-23. doi: 10.1093/fampra/cmz013
10. Salisbury C. Multimorbidity: Redesigning health care for people who use it: *The Lancet*. 379 (9836) (pp 7-9), 2012. Date of Publication: July 2012. 2012.
11. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. *Age and ageing* 2012;42(1):62-69.
12. Farmer C, Fenu E, O'flynn N, et al. Clinical assessment and management of multimorbidity: summary of NICE guidance. *BMJ: British Medical Journal (Online)* 2016;354
13. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. *International journal of epidemiology* 2018;47(2):382-84f.
14. Mercer SW, Gunn J, Wyke S. Improving the health of people with multimorbidity: the need for prospective cohort studies: SAGE Publications Sage UK: London, England, 2011.
15. France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: a systematic review of prospective cohort studies. *Br J Gen Pract* 2012;62(597):e297-e307.
16. Muth C, Beyer M, Fortin M, et al. Multimorbidity's research challenges and priorities from a clinical perspective: The case of 'Mr Curran': *European Journal of General Practice*. 20 (2) (pp 139-147), 2014. Date of Publication: June 2014. 2014.
17. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity is common to family practice: is it commonly researched?: *Canadian family physician Medecin de famille canadien*. 51 (pp 244-245), 2005. Date of Publication: Feb 2005. 2005.
18. Kadam U. Redesigning the general practice consultation to improve care for patients with multimorbidity: *BMJ (Online)*. 345 (7878) , 2012. Article Number: e6202. Date of Publication: 13 Oct 2012. 2012.
19. Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. *Bmj* 2012;345:e5205.
20. Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. *Bmj* 2015;350(176):10.1136.
21. Centre for Health Protection DoH, The Government of the Hong Kong Special Administrative Region, . Life Expectancy at Birth (Male and Female), 1971 - 2017 <https://www.chp.gov.hk/en/statistics/data/10/27/111.html> 2018;Availabe on July 23 2018
22. The Government of Hong Kong Special Administrative Region. 2016 Population By-census. <http://www.by2016.gov.hk/en/bc-mthtml> 2018;Accessed on July 31, 2018
23. Hospital Authority HKS. Hospital Authority Annual Report 2016-2017. <http://www.ha.org.hk/ho/corpcomm/AR201617/ebook/en/mobile/index.html#p=1> 2018

24. Yu XN, Stewart SM, Wong PTK, et al. Screening for depression with the Patient Health Questionnaire-2 (PHQ-2) among the general population in Hong Kong. *Journal of Affective Disorders* 2011;134(1-3):444-47. doi: 10.1016/j.jad.2011.05.007
25. Yu X, Tam WW, Wong PT, et al. The Patient Health Questionnaire-9 for measuring depressive symptoms among the general population in Hong Kong. *Comprehensive psychiatry* 2012;53(1):95-102.
26. Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *General hospital psychiatry* 2016;39:24-31.
27. Leung GT, de Jong Gierveld J, Lam LC. Validation of the Chinese translation of the 6-item De Jong Gierveld Loneliness Scale in elderly Chinese. *International psychogeriatrics* 2008;20(6):1262-72. doi: 10.1017/S1041610208007552
28. Doris S. Insomnia Severity Index: psychometric properties with Chinese community-dwelling older people. *Journal of advanced nursing* 2010;66(10):2350-59.
29. Ngai SP, Cheung RT, Lam PL, et al. Validation and reliability of the Physical Activity Scale for the Elderly in Chinese population. *Journal of rehabilitation medicine* 2012;44(5):462-65.
30. Rolfson DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton Frail Scale. *Age and ageing* 2006;35(5):526-29.
31. Zhang D, Chan DC-C, Niu L, et al. Meaning and its association with happiness, health and healthcare utilization: A cross-sectional study. *Journal of affective disorders* 2018;227:795-802.
32. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. *Journal of the American Medical Directors Association* 2013;14(8):531-32.
33. Woo J, Leung J, Morley JE. Validating the SARC-F: A suitable community screening tool for sarcopenia? *Journal of the American Medical Directors Association* 2014;15(9):630-34.
34. Wong A, Xiong YY, Kwan PW, et al. The validity, reliability and clinical utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. *Dementia and geriatric cognitive disorders* 2009;28(1):81-87.
35. Wong EL, Ramos-Goñi JM, Cheung AW, et al. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong. *The Patient-Patient-Centered Outcomes Research* 2018;11(2):235-47.
36. Wong SY, Zou D, Chung RY, et al. Regular Source of Care for the Elderly: A Cross-National Comparative Study of Hong Kong With 11 Developed Countries. *J Am Med Dir Assoc* 2017;18(9):807 e1-07 e8. doi: 10.1016/j.jamda.2017.05.009 [published Online First: 2017/06/26]
37. Census, Residents SDJHSO HK. Thematic Household Survey Report No. 50: Census and Statistics Department Hong Kong SAR, 2013.
38. Organization WH. The global burden of disease: 2004 update. 2008, 2011.
39. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X

- 1
2
3 40. Gunn JM, Ayton DR, Densley K, et al. The association between chronic illness,
4 multimorbidity and depressive symptoms in an Australian primary care cohort. *Social*
5 *psychiatry and psychiatric epidemiology* 2012;47(2):175-84. doi: 10.1007/s00127-010-
6 0330-z
7
8 41. Stickley A, Koyanagi A. Physical multimorbidity and loneliness: A population-based study.
9 *PloS one* 2018;13(1):e0191651. doi: 10.1371/journal.pone.0191651
10
11 42. Vancampfort D, Koyanagi A, Hallgren M, et al. The relationship between chronic physical
12 conditions, multimorbidity and anxiety in the general population: A global perspective
13 across 42 countries. *General hospital psychiatry* 2017;45:1-6. doi:
14 10.1016/j.genhosppsy.2016.11.002
15
16 43. Wang YM, Song M, Wang R, et al. Insomnia and Multimorbidity in the Community Elderly
17 in China. *Journal of clinical sleep medicine : JCSM : official publication of the American*
18 *Academy of Sleep Medicine* 2017;13(4):591-97. doi: 10.5664/jcsm.6550
19
20 44. Kanesarajah J, Waller M, Whitty JA, et al. Multimorbidity and quality of life at mid-life: A
21 systematic review of general population studies. *Maturitas* 2018;109:53-62. doi:
22 10.1016/j.maturitas.2017.12.004
23
24 45. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity and quality of life in primary care: a
25 systematic review. *Health Qual Life Outcomes* 2004;2:51. doi: 10.1186/1477-7525-2-51
26
27 46. Wang L, Palmer AJ, Cocker F, et al. Multimorbidity and health-related quality of life
28 (HRQoL) in a nationally representative population sample: implications of count versus
29 cluster method for defining multimorbidity on HRQoL. *Health Qual Life Outcomes*
30 2017;15(1):7. doi: 10.1186/s12955-016-0580-x
31
32 47. Xie G, Laskowitz DT, Turner EL, et al. Baseline health-related quality of life and 10-year
33 all-cause mortality among 1739 Chinese adults. 2014;9(7):e101527.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Core topic areas in questionnaires and examinations in the

Assessment	Description
<i>Questionnaire</i>	
Use of medication	number and duration (0-1 year/2-5 years/>5 years) for antihypertensive, cardiovascular and hypolipidemic drugs, antidiabetics, antipsychotics and analgesics
Compliance of medication use	“At times, do you forget to take your prescription medications?” (no/yes)
Depression	The 2-item Patient Health Questionnaire (PHQ-2) for depression; The 9-item Patient Health Questionnaire (PHQ-9) for those with PHQ-2 \geq 3
Anxiety	The 2-item Generalised Anxiety Disorder (GAD-2); The 7-item Generalised Anxiety Disorder (GAD-7) for those with GAD-2 \geq 3
Loneliness*	De Jong Gierveld Loneliness Scale; and one question asking “Do you feel lonely? (Yes/No)” (added at a later stage)
Insomnia	The 7-item Insomnia Severity Index (ISI) for those answered yes to the screening question “In the past two weeks, do you have insomnia? (Yes/No)”
Pain	A screening question of “In the past year, do you have musculoskeletal pain for at least 3 months”, for those who answered ‘yes, one pain area or ‘yes, two or more pain areas’, Brief Pain Inventory (BPI) was measured.
Physical activity	For those were screened positive in pain, Physical Activity Scale for the Elderly (PASE) was measured
Self-rated health	“In general, how will you describe your health? (extremely good, very good or good/fair/poor)
Community network	“When you need help, do you have someone who is willing to and able to meet your needs?” (always/sometimes/never)
Meaning of existence*	One item extracted from the validated reliable Chinese Purpose in Life test (CPIL)
Use of social media	A screening question of “In the past two weeks, have you ever used the following social media”, for those who answered yes to any of the social media, they were further assessed with importance and comfort of using internet.
Oral health*	“Do you have any difficulty when biting or chewing foods (even with the use of denture)” (yes/no)
Incontinence*	“Do you have incontinence?” (yes/occasionally/no)
Frailty*	The Edmonton Frail Scale

Sarcopenia*	The 5-item Sarcopenia Assessment (SARC-F)
Cognition	Mainly assessed with Montreal Cognitive Assessment Hong Kong version (HK-MoCA) but in an earlier stage, Abbreviated Memory Inventory for Chinese (AMIC) was used.
Quality of life	The EuroQol EQ-5D-5L (EQ5D)
Daily Function	Instrumental Activities of Daily Living (IADL) including ability to use telephone, mode of transportation, shopping, food preparation, ability to handle finances
Use of health services	Visits to primary care doctors, specialist outpatient clinics, admission to hospital, use of services in elderly daycare centers and out-of-pocket healthcare cost both in private and public in the past year
Alcohol use	The 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C) for those who drank alcohol in the past year
Tobacco use	One question asking for current, ex- and non-smoking behavior
Caregiving to somebody else	“Are you taking care of somebody?” (Yes/No)
Social economical status	Age, gender, marriage, living status, employment, receiving of social welfare scheme
<u>Physical examination</u>	
Blood pressure	Measured twice in 15 minutes after rest
Weight, height and BMI	
Waist circumference	
Handgrip strength	Each hand was measured twice
<u>Electronic health record and self-report data</u>	
Chronic diseases	43 common chronic conditions in fifteen categories including diseases of metabolic system, cancer, heart, respiratory system, liver and gallbladder, stomach and intestine, musculoskeletal and connective tissue, kidney and reproductive system, ear nose and throat (ENT), eye, blood, nervous system, mental disorders and others
Use of medication	Medication use number and duration (0-1 year/2-5 years/>5 years) for antihypertensive drugs, cardiovascular drugs, cholesterol-lowering drugs, antidiabetics, antipsychotics and analgesics

* Measures were added at later stages: about 712 to 995 patients received these measures.

Table 2 Baseline characteristics of the elderly with multimorbidity in the cohort (n=1080) and comparison with another two population-based surveys

Characteristics	Multimorbidity Cohort		Elderly Telephone Survey	Thematic Household Survey 2011	
	N=1080	N=414	p	N=2301	p
Female	69.9%	67.4%	0.3483	55.7%	<0.001
Age (mean, sd)	70.0 (6.8)				
60-64	21.8%	15.5%	<0.001	18.4%	<0.001
65-69	32.8%	18.8%		16.8%	
70-74	22.7%	20.5%			
75-79	11.7%	12.6%		64.8%	
80 or above	11.0%	32.6%			
Marriage					
married	67.4%	74.2%	<0.001	61.1%	<0.001
single/divorced/separated	9.6%	2.2%		7.4%	
widowed	23.1%	23.4%		31.4%	
No. of children (mean, sd)	2.52 (1.47)				
Living alone	14.1%			18.9%	<0.001
Employment					
Retired/ Housewife	91.9%			92.4%	0.629
Employed	8.1%			7.6%	
Education (year, mean, sd)	7.7 (4.6)				
Year of education \geq 6 years	49.3%	30.7%	<0.001	31.6%	<0.001
Social security recipient					
Comprehensive Social Security Assistance (CSSA) Scheme	58.6%	75.8%	<0.001		
Fruit Voucher	10.2%	5.3%	0.003	10.7	0.628
Disability allowance	46.4%				
Other	3.5%	2.9%	0.551	2.4%	0.062
Caregiving to somebody	17.5%				
Number of chronic conditions (mean, sd)	4.1 (1.8)				
2 diseases	19.5%	64.5%	<0.001	47.4%	<0.001
3 diseases	26.4%	25.8%		29.7%	
4 diseases	19.8%	6.8%		13.1%	
5 disease	14.4%	2.2%		6.1%	
6+ disease	19.8%	0.7%		5.4%	
Chronic conditions by category					
Metabolic diseases	83.6%				
Cancer	9.0%				
Cardiovascular diseases (CVD)	16.9%				
Respiratory disease	7.2%				
Liver disease	9.5%				
Gastrointestinal disorders	26.8%				
Musculoskeletal disorders (MSK)	60.4%				
Thyroid disease	7.3%				
Renal disease	11.7%				
ENT	9.0%				
Eye	26.3%				
Skin	9.5%				
Anemia	3.0%				
Neurological disease	0.8%				
Mental illness	14.9%				
Self-rated health					
Excellent/very good/good	28.4%	25.8%	<0.001	29.2%	<0.001
Fair	59.2%	52.7%		52.7%	
Poor	12.4%	21.5%		18.2%	

Use of medication		
Antihypertensive drugs (mean, sd)		1.1 (0.9)
Percentage of patients who use		71.0%
Cardiovascular drugs (mean, sd)		0.2 (0.5)
Percentage of patients who use		15.3%
Antidiabetics (mean, sd)		0.4 (0.8)
Percentage of patients who use		25.3%
Cholesterol-lowering drugs (mean, sd)		0.4 (0.5)
Percentage of patients who use		41.6%
Antipsychotics (mean, sd)		0.2 (0.7)
Percentage of patients who use		10.6%
Analgesics (mean, sd)		0.1 (0.5)
Percentage of patients who use		10.8%
Total number of medication (mean, sd)		2.4 (1.9)
% forgetting taking medication (n=995)		37.1%
Quality of life (EQ5D-5L)		
Index score (range: -0.864 to 1)		-0.6 (0.2)
visual analogue scale (VAS) (0-100)		67.0 (14.8)
Depression		
PHQ-2		
Screen (-) (<3)		80.9%
Screen (+) (≥3)		19.1%
PHQ-9 (mean, sd) ^a		
Normal (0-4)		81.2%
Mild (5-9)		7.4%
Moderate (10-14)		6.8%
Moderately severe (15-19)		3.4%
Severe (20+)		1.2%
Anxiety		
GAD-2 (≥3) (mean, sd)		
Screen (-) (<3)		83.0%
Screen (+) (≥3)		17.0%
GAD-7 (mean, sd) ^b		
Very mild (0-4)		0.7%
Mild (5-9)		6.3%
Moderate (10-14)		7.7%
Severe (15+)		2.3%
Loneliness (n=741)		
One question (yes/no)		
No		72.3%
Yes		27.7%
De Jong Gierveld Loneliness Scale		
Total loneliness score (mean, sd)		1.64 (1.76)
Emotional loneliness score (mean, sd)		0.90 (1.02)
Social loneliness score (mean, sd)		0.74 (1.25)
Insomnia		
Insomnia in the past 2 weeks		
No		33.4%
Yes		66.6%
ISI (n=719) (mean, sd) ^c		
No clinically significant insomnia (0-7)		48.4%
Subthreshold insomnia (8-14)		30.4%
Clinical insomnia, moderate severity (15-21)		20.0%
Clinical insomnia, severe (22-28)		1.2%
Social Support (can count on someone willing and able to meet your needs)		
Always		62.6%
Sometimes		30.7%
Never		6.7%
Oral Health Problem (n=995)		
		24.1%
Incontinence (n=995)		

No	79.6%			
Occasionally	18.9%			
Yes	1.5%			
Pain				
Muscle-skeletal pain for at least 3 months in the past year				
No	24.8%			
Yes, one pain area	10.8%			
Yes, two or more pain areas	64.4%			
Brief Pain Inventory (BPI) ^c				
Interference (n=812)	4.5 (1.9)			
Severity (n=813)	2.7 (2.1)			
Physical Activity Scale for the Elderly (PASE) (n=812) ^d				
Mean (SD)	80.3 (43.3)			
Use of social media in last 2 weeks				
Yes	52.5%			
Web	24.6%			
Whatsapp	50.8%			
Facebook	17.2%			
Blog	2.2%			
E-literacy (n=566) ^e	25.0 (12.0)			
Importance of social media (total score: 6-24)	11.1 (4.8)			
Comfort of using social media (total score: 3-18)	8.2 (4.5)			
Frailty				
Edmonton Frail Scale (EFS) (mean, sd) (n=992) ^f				
No frailty (0-5)	3.4 (2.2)			
Apparently vulnerable (6-7)	82.5%			
Mild frailty (8-9)	12.3%			
Moderate frailty (10-11)	4.1%			
Severe frailty (12-18)	1.0%			
	0.1%			
Sarcopenia (mean, sd) (n=719) ^f				
Positive (≥ 4)	1.2 (1.5)			
Negative (0-3)	7.9%			
	92.1%			
Daily function (Percentage of patients needing help or being dependent)				
Using telephone	0.8%			
Transportation	4.3%			
Shopping	5.5%			
Preparing meals	6.8%			
Financial management	3.5%			
Total	10.3%			
Alcohol use				
Yes, in last 12 months	12.6%			
AUDIT-C ^g				
AUDIT-C positive (≥ 3)	4.4%			
Smoke				
Never smoke	86.1%	79.6%		<0.001
Smoke	2.7%	7.2%		
Quit smoke	11.2%	13.3%		
Meaning (0-7)				
	4.8 (1.2)			
Cognition ^h				
AMIC (mean, sd) (n=338)				
AMIC Positive % (≥ 3)	2.1 (1.7)			
	37.3%			
HK-MOCA (n=787)				
HK-MOCA Abnormal % (< 22)	24.9 (4.0)			
	15.9%			
Health care utilization in the past year				
Hopitalisation frequency				
0	83.0%	82.2%	0.702	82.4% <0.001

1	1	15.3%		11.4%	
2	2+	1.8%	17.8%	6.2%	
3	Hospitalisation Length (days, mean, sd)	1.2 (6.2)			
4	Specialist Out-patient Clinics (SOPC)	69.6%		84.2%	
5	General Out-patient Clinics (GOPC)	91.0%			<0.001
6	Elderly day care service	9.6%			
7	Cost (out of pocket) (HKD) median (interquartile range, IQR)	1000 (0, 3000)			
8					
9					
10	Physical examinations				
11	Blood pressure (BP)				
12	Systolic (mean, sd)	133.5 (15.7)			
13	Diastolic (mean, sd)	75.9 (9.9)			
14	Normal (SBP <120 & DBP <80)	17.9%			
15	Pre-hypertension (SBP: 120-139 or DBP: 80-89)	46.5%			
16	Stage I hypertension (SBP: 140-159 or DBP: 90-99)	30.3%			
17	Stage II hypertension (SBP ≥ 160 or DBP ≥ 100)	5.3%			
18	Pulse (per minute)	72.7 (22.4)			
19	Weight (kg, mean, sd)	60.2 (10.4)			
20	Height (cm, mean, sd)	157.4 (8.2)			
21	Waist circumference (cm, mean, sd)	90.2 (9.9)			
22	Body mass Index (BMI) (mean, sd)	24.2 (3.6)			
23	Underweight (<18.5)	3.7%			
24	Normal (18.5-22.9)	35.6%			
25	Overweight (23-24.9)	22.1%			
26	Obese (≥ 25)	38.6%			
27					
28	Handgrip strength (kg) ⁱ				
29	Left hand (mean, sd)	20.1 (6.6)			
30	Right hand (mean, sd)	21.1 (6.8)			
31	Both hand (mean, sd)	21.9 (6.7)			

Inclusion Criteria of participants in the Elderly Telephone Survey and Thematic Household Survey 2011): 1) age ≥ 60; 2) number of chronic conditions ≥ 2. Chi-square tests were used for comparisons between the current cohort and the two surveys.

Abbreviations: GAD-2: the two-item General Anxiety Disorder scale; HK-MoCA: Montreal Cognitive Assessment Hong Kong version (HK-MoCA); ISI: the 7-item Insomnia Severity Index; EQ5D: the EuroQol EQ-5D-5L; PHQ-2: The two item Patient Health Questionnaire for depression; The 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C); SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure.

Notes:

^a Mean (SD) was for 206 patients who did PHQ-9. The % was for all the 1080 patients with the rest 874 patients who screened negative in PHQ-2 regarded as having normal scores in PHQ-9.

^b Mean (SD) was for 184 patients who did GAD-7. The % was for all the 1080 patients with the rest 896 patients who screened negative in GAD-2 regarded as having normal scores in GAD-7.

^c 719 patients were assessed with ISI. 361 patients who were screened negative in the screening question, was regarded as having no clinically significant insomnia.

^d Only those who had one or more pain areas in the past 3 months were assessed with BPI or PASE-C.

^e Only those who had social media use in the past 2 weeks were assessed.

^f Measured by the 5-item Sarcopenia Assessment (SARC-F) which were added at a later stage.

^g N=136, those who did not drink alcohol the past 12 months were regarded as 0 in AUDIT-C.

^h HK-MOCA replaced AMIC in a later stage.

ⁱ Better result of two series for left or right hand, or best result of both hands.




Figure 1 Flowchart of recruitment



Figure 2 Prevalence of co-morbidities (by 15 disease categories) among the 1080 elderly with multimorbidity

(Figures are prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK: Musculoskeletal Disorders; ENT: eye, nose and throat)




Figure 3 Prevalence of the top 10 co-morbidities (out of 43 specific chronic conditions) among the 1080 elderly with multimorbidity (Figures are prevalence (%))

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4–5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5–6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5–7, 10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5–6, 10
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6–7, Table 1
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6–7, Table 1
Bias	9	Describe any efforts to address potential sources of bias	6–7
Study size	10	Explain how the study size was arrived at	5–6, Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	NA
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7, Table 2
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	Table 2
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1

1	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-10, Table 2
2			(b) Indicate number of participants with missing data for each variable of interest	Table 2
3			(c) Summarise follow-up time (eg, average and total amount)	10
4	Outcome data	15*	Report numbers of outcome events or summary measures over time	8-10, Table 1
5	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
6			(b) Report category boundaries when continuous variables were categorized	Table 2
7			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
8	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
9	Discussion			
10	Key results	18	Summarise key results with reference to study objectives	10-11
11	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
12	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
13	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
14	Other information			
15	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Biopsychosocial health profile of Chinese elderly with multimorbidity in Hong Kong

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027279.R1
Article Type:	Original research
Date Submitted by the Author:	24-May-2019
Complete List of Authors:	ZHANG, Dexing; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Sit, Regina Wing Shan; The Chinese University of Hong Kong, JC School of Public Health and Primary Care Wong, Carmen; The Chinese University of Hong Kong , Jockey Club School of Public Health and Primary Care Zou, Dan; The Chinese University of Hong Kong, JC School of Public Health and Primary Care Mercer, Stewart; University of Glasgow, Institute of Health and Wellbeing Johnston, Marjorie; University of Aberdeen, Wong, Samuel; Chinese University of Hong Kong, School of Public Health and Primary Care
Primary Subject Heading:	Patient-centred medicine
Secondary Subject Heading:	Epidemiology, Evidence based practice, General practice / Family practice, Geriatric medicine, Health services research
Keywords:	Chronic conditions, Comorbidities, Older Adults, General practice, Physical, Psychological and Social Factors, PRIMARY CARE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Biopsychosocial health profile of Chinese elderly with multimorbidity in Hong Kong**

2 Dexing Zhang,¹ Regina Wing Shan Sit,¹ Carmen Wong,¹ Dan Zou,¹ Stewart W. Mercer,² Marjorie
3 Johnston,³ Samuel Yeung Shan Wong^{1*}

- 4
- 5 1. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR
- 6 2. The Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh,
7 The United Kingdom
- 8 3. The Institute of Applied Health Sciences, University of Aberdeen, The United Kingdom

10 *** Corresponding Author:**

11 Name: Samuel Yeung Shan WONG
12 Email: yeungshanwong@cuhk.edu.hk
13 Tel: (852) 2252 8774
14 Fax: (852) 2606 3500
15 Address: 4/F, JC School of Public Health and Primary Care, Prince of Wales Hospital, Shatin, N.T., Hong
16 Kong

18 **Funding**

19 The work was supported by The Hong Kong Jockey Club Charities Trust.

20 **Acknowledgements**

21 We would like to thank the General Out-patient Clinics (Lek Yuen, Ma On Shan, Shatin (Tai Wai), Yuen Chau Kok)
22 and Shatin Rhenish Neighbourhood Elderly Centre for the support to the project. We thank Dicken Chan and Lilian
23 Wen Sun in preparation of some of the data. We also greatly thank all the patients who joined in the study.

24 **Patient consent** Obtained

25 **Ethics approval** Compliance with Ethical Standards. Ethics approval was obtained from the Joint Chinese University
26 of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee (The Joint CUHK-NTEC CREC).

27 **Conflict of Interest** None declared

28 **Contributors** SYSW conceived and supervised the study and revised the manuscript. DXZ contributed to study design,
29 analyzed the data, prepared the draft and revised the manuscript. SRWS and CW contributed to the study design and
30 implementation, and manuscript revisions. DZ contributed to data collection and manuscript revisions. SWM and MJ
31 contributed to manuscript revisions.

32
33 **Word count:** 3721 words (excluding abstract, references, tables and figures)

1 ABSTRACT

2 3 **Objectives**

4 To examine the biopsychosocial health profile of elder patients with multimorbidity in Hong Kong.

5 **Design**

6 Cross-sectional study, with results weighted according to the census.

7 **Setting**

8 Four public primary care clinics in Hong Kong.

9 **Participants**

10 A total of 1077 patients aged 60 years or above with at least two chronic diseases.

11 **Primary and secondary outcome measures**

12 Biopsychosocial health indicators (primary), healthcare utilization and quality of life (secondary).

13 **Results**

14 After weighting, they had 4.1 (1.8) chronic conditions and 2.5 (1.9) medications on average; 37% forgot
15 taking medication sometimes; 71% rated their health as fair or poor; 17% were frail; 73% reported one
16 (21%) or two or more (52%) body pain areas; 62% were overweight/obese; 23% reported chewing difficulty,
17 18% reported incontinence; 36% had current Stage 1/2 hypertension; 38% had handgrip strength below the
18 cut-off; 18% screened positive in sarcopenia; 12% had mild cognitive impairment; 17% had mild
19 depression or severer; 17% had mild anxiety or severer; 50% had sub-threshold insomnia or severer; 28%
20 indicated being lonely; the EQ-5D-5L index score was 0.81 (0.20) and visual analogue scale (VAS) score
21 was 67.6 (14.6); 12% needed help in at least one out of the five daily functions. In the past 12 months, 17%
22 were hospitalized, 92% attended general out-patient clinics (GOPC), 70% attended specialist out-patient
23 clinics (SOPC), and 10% used elderly daycare center services, the median out-of-pocket health cost was
24 1000 HK\$ (US\$150). Female and male patients showed significant differences in many biopsychosocial
25 health aspects.

26 **Conclusions**

27 The weighted results might have underestimated the situation in elder primary care patients and be close to
28 the situation of the general elderly. In addition to physical problems, elder primary care patients with
29 multimorbidity are also affected by significant psychological and social problems. A holistic approach
30 addressing physical, psychological and social health problems is greatly needed.

31 **Study Registration** ChiCTR-OIC-16008477

32 33 **Key Words:**

- 1
- 2
- 3 1 Chronic conditions; Comorbidities; Older Adults; General practice; Physical, Psychological and Social
- 4
- 5 2 Factors; Primary Care
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

Strengths and limitations of this study

- The study examines biopsychosocial health problems encountered by Chinese elderly with multimorbidity in a primary care program in Hong Kong. The results were weighted according to the census data. The information could be helpful to healthcare providers, policy makers and researchers.
- The data could be linked with health electronic records to allow follow up and examination of long-term outcomes associated with multimorbidity.
- The limitation was that older adult patients who were male, disabled, very ill, institutionalized, or house-bounded were less likely to have participated in this study; and a few assessments were only conducted within subgroups or added at a later stage. The weighted rates might be an underestimation of the rates among the primary care patients and be close to the rates of the general population.

1 INTRODUCTION

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Multimorbidity, defined as having two or more chronic health conditions, is common in primary care. The prevalence has increased in recent decades as a result of an aging population and changes in lifestyles e.g. more sedentary lifestyles which have increased the risk of obesity, resulting in a higher risk of developing chronic conditions.^{1 2} A recent systematic review suggests that the prevalence of multimorbidity is high among the elderly ranging from 12.9% to 95.1% in different studies.³ Multimorbidity is associated with increased disability and depression, reduced quality of life, and higher rates of adverse drug consequences.⁴ Multimorbidity also leads to increased primary and secondary health service utilization, especially unplanned health care, as well as reduced life-expectancy.⁵ The direct and indirect economic burden associated with multimorbidity is huge.⁶ The annual healthcare costs were €4,096.86 among patients with 5 or more chronic conditions, which was almost 5 times more than those who were healthy in a study in the West of Ireland.⁷ It has been estimated that by 2030, 66% of the global disease burden will be due to chronic diseases, with most of the burden occurring in the most populous area – Asia.^{8 9} The economic burden highlights an urgent need to search for cost-effective ways to manage patients with multimorbidity, given that treatment of diseases in isolation can be inefficient, leading to duplication of care and poorer health outcomes.¹⁰

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Studies of multimorbidity have increased in recent years,¹¹⁻²⁰ and a clinical guideline on clinical assessment and management of multimorbidity was developed by the National Institute for Health and Care Excellence (NICE) in the UK in 2016.²¹ However, studies are still needed for the epidemiology and profiles of patients with multimorbidity and their longitudinal outcomes to inform policy making in different populations including Chinese primary care patients.^{3 22} Most studies on primary care patients with multimorbidity are conducted in western countries such as UK, USA, Australia, Spain and Belgium,^{14 15 23-29} and limited research has been conducted on psychological and social problems accompanying with multimorbidity.^{3 21 22 30 31} Several longitudinal studies of multimorbidity have been conducted in Asian populations,³²⁻³⁴ but none of these are of primary care patients. Important knowledge gaps still exist regarding the biopsychosocial health profiles of elderly people with multimorbidity in primary care in Asian Chinese elderly.³⁵ Therefore, more studies among Chinese elderly with multimorbidity in primary care are needed to advance our understanding for services.^{14 36-40}

1
2
3 1 This study focuses on the elderly in Hong Kong, where the population is ageing rapidly.
4
5 2 Hong Kong has a population of 7.34 million according to the 2016 census data, with 23.7% aged
6
7 3 60 years or above. This was higher than the proportions in 2006 (16.5%) and 2011 (19.5%).⁴¹ In
8
9 4 Hong Kong, although there is a large private primary care sector, around 85% of people with
10
11 5 chronic conditions are managed in the public primary care setting. Given that the Hong Kong
12
13 6 population has the longest life expectancy in the world: (81.7 for men and 87.7 for women in
14
15 7 2017),⁴² the ageing population and multimorbidity have brought much burden and challenge to the
16
17 8 local healthcare system. To inform healthcare providers and policymakers in providing suitable
18
19 9 health services for people with multimorbidity in primary care, the present study aimed to study
20
21 10 the biopsychosocial health profiles of Chinese patients with multimorbidity who present to public
22
23 11 primary care in Hong Kong.
24
25 12
26 13

25 14 **METHODS**

26 15 **Study design**

27
28 16 This cross-sectional study reports the baseline data of a primary care programme for
29
30 17 multimorbidity in Hong Kong.
31
32 18

33 19 **Study setting and participants**

34
35 20 This study contains primary care patients from four general out-patient clinics (GOPCs) out of the
36
37 21 ten general out-patient clinics (GOPCs) in the New Territory East Cluster (NTEC), Hong Kong,
38
39 22 as permission to recruit from these four was given by the local regulator (the Hospital Authority).
40
41 23 Each GOPC sees about 450 patients each day. The working hours are generally from 9:00 am to
42
43 24 5:00 pm from Monday to Friday with some additional night and weekend sessions. In the most
44
45 25 recent Hospital Authority Annual Report 2016-2017, the ten GOPCs in NTEC provided 972,454
46
47 26 consultations in total in the year of 2015/2016, which consisted of one third of total GOPC
48
49 27 consultations in Hong Kong public health system.⁴³

50
51 28 The inclusion criteria of participants were: 1) aged 60 years or above; 2) with two or more
52
53 29 chronic diseases confirmed by the medical information in the public Clinical Management System
54
55 30 (CMS) and patients' self-report; and 3) could speak and understand Chinese. No specific exclusion
56
57 31 criteria were adopted. However, as participants needed to respond to questionnaire surveys and

1 health checks, they should be able to access the clinic, sign informed consent by themselves, and
2 understand and answer the research questions.

3 Patients were first consecutively screened for eligibility by trained research assistants in
4 the waiting areas of the GOPCs. For those who were eligible, they were asked to provide a contact
5 phone number and then were scheduled to visit the study nurse for further assessments. All patients
6 provided informed consent before participation in the study. From April 2016 to October 2017,
7 1077 eligible patients were recruited and completed the baseline assessments. The sample size
8 allowed a margin of error at 3% with a confidence interval of 95%. The flowchart of recruitment
9 is shown in **Figure 1**. The baseline assessments were conducted through face-to-face interviews
10 by nurses or a social worker at a university affiliated primary care clinic.

11 **Measurements**

12 The assessments covered a range of measures that are postulated to be potential physical,
13 psychological and social factors associated with multimorbidity. Each complete assessment lasted
14 for about 45 to 60 minutes. All the measures were validated and have been widely used or have
15 been used in our previous studies. Information was collected through face-to-face interviews by
16 trained nurses and social workers, and additional information of the disease entities, medication
17 use and health service utilization was confirmed through the review of electronic medical records
18 by nurses. The electronic medical records include patient information and diagnosis, health
19 examinations, medication prescription, and health visits to the public health system. The records
20 cover all patients who seek medical services in public health system. It is a medical record system
21 of routine clinical practices with quality ensured by all healthcare professionals including trained
22 doctors, nurses and allied health professionals under Hospital Authority in Hong Kong.

23 The measures in the questionnaires included: 1) the number and type of chronic diseases
24 in fifteen categories (a total of 43 chronic conditionals) adapted slightly by a group of family
25 physicians and researchers based on chronic conditions in previous studies^{44 45} and the
26 International Statistical Classification of Diseases 11 (ICD-11). Details can be seen in Table 1; 2)
27 depression (screened by the 2-item Patient Health Questionnaire (PHQ-2)).⁴⁶ Those with a score
28 of 3 or more (which suggests depression) were further measured by the 9-item Patient Health
29 Questionnaire (PHQ-9);⁴⁷ 3) anxiety (screened by the 2-item Generalised Anxiety Disorder (GAD-
30 2)). Those with a score of 3 or more (which suggests anxiety) were further measured by the 7-item

1
2
3 1 Generalised Anxiety Disorder (GAD-7);⁴⁸ 4) loneliness (measured by the 6-item De Jong Gierveld
4 Loneliness Scale),⁴⁹ as well as one loneliness question; 5) insomnia (measured by the 7-item
5 Insomnia Severity Index (ISI))⁵⁰ among those who answered yes to a screening question); 6) pain
6 (measured by the Brief Pain Inventory among those who were screened positive in pain); 7)
7 physical activity (measured by Physical Activity Scale for the Elderly (PASE)⁵¹ among those who
8 were screened positive in pain); 8) frailty (measured by the Edmonton Frail Scale⁵² which was
9 translated and back-translated by experienced bilingual translators); 9) meaning of existence
10 (measured by one question extracted from the validated Chinese Purpose in Life test (CPIL) which
11 was used in a previous study);⁵³ 10) sarcopenia (measured by the 5-item Sarcopenia Assessment
12 (SARC-F));^{54,55} 11) cognition (measured by the Hong Kong Montreal Cognitive Assessment (HK-
13 MoCA) with a score of 22 or above being with normal cognition);⁵⁶ 12) alcohol use (screened by
14 one question and then measured by the 3-item Alcohol Use Disorders Identification Test-
15 consumption (AUDIT-C) for those who screened positive); 13) smoking (non-smoker, current
16 smoker, ex-smoker); 14) medication use (number and duration (0-1 year/2-5 years/>5 years) of
17 antihypertensive, cardiovascular and hypolipidemic drugs, antidiabetics, antipsychotics and
18 analgesics was checked in electronic medical system, and compliance of medication use was
19 measured by “At times, do you forget to take your prescription medications?” (no/yes)); 15) self-
20 rated health; 16) community network; 17) use of social media (measured by a screening question,
21 and for those who answered yes to any of the social media, they were further assessed on the
22 importance and comfort of using the internet); 17) oral health; 18) incontinence; 19) caregiving to
23 somebody; 20) quality of life was measured by the EuroQol EQ-5D-5L (EQ5D);⁵⁷ 21) daily
24 function (ability to use the telephone, mode of transportation, shopping, food preparation, ability
25 to handle finances were measured); 22) health service utilization was based on visits to primary
26 care doctors, specialist outpatient clinics, admission to hospital, use of services in elderly daycare
27 centers and out-of-pocket healthcare costs which were not covered by public health system or
28 insurance both in private and public in the past year. In addition, physical examinations included
29 blood pressure, Body Mass Index (BMI), waist circumference and handgrip strength (kg). For
30 blood pressure, two assessments were taken by the nurses. Patients sat for at least 5 minutes before
31 the first assessment, and they were assessed again 15 minutes later. Handgrip strength was also
32 assessed twice for each hand. Social economic status such as age, gender, marriage, living status,
33 employment, receiving of social welfare scheme was also included. Due to the data collection plan

1 amendments, some measures were only collected in a sub-group of the patients at a later stage.
2 Summaries of the baseline measures are described in **Table 1**.

3 The questionnaire was set up in password protected EpiData files in a password protected
4 computer with quality control. For example, for scale questions with answers on a Likert scale of
5 1 to 5, a range of 1-5 and one digit was set up so no other results were allowed during data entry.
6 Additionally, for most data variables, a “must enter” was set up, so that the question could not be
7 missed unless answered or an individual purposely moves to the next question. Checking for
8 missing data was done regularly by experienced researchers and missing data was further collected
9 by nurses through face-to-face interviews, telephone or by checking the electronic medical record
10 system.

11 **Data analysis**

12 Data was described using mean (standard deviation), median (interquartile range) and percentages.
13 Differences between male and female patients were analyzed. Chi square tests were used for
14 analyzing categorical variables. T tests and non-parameter tests were used for analyzing
15 continuous variables with normal and non-normal distributions, respectively. The results were
16 further weighted according to age, gender, and marital status of the elderly aged 60 or above
17 based on the Hong Kong 2016 Population By-census data from the Census and Statistics
18 Department of Hong Kong government.⁵⁸ Linear regression and logistic or ordinal regression
19 was used for analyzing gender differences with the weighted data for the continuous and
20 categorical results, respectively. Stata 12 and SPSS 20 were used for data analysis. P values \leq
21 0.05 (two sides) were regarded as statistically significant.

22 **Patient and Public Involvement**

23 The research questions and outcome measures were developed based on health and social problems
24 which are widely regarded as common in older people. Patients or the public were not involved in
25 the design of the study, recruitment or conduction of the study. The results of the study will be
26 disseminated to patients if he or she requests so, and aggregated data will be reported in project
27 reports, research publications and conferences.

1 RESULTS

2 Participants

3 Baseline characteristics of the patients in the study are shown in **Table 2**. The weighted data are
4 shown in the bracket beside the unweighted data. The mean age of the study patients was 70
5 (SD=6.8) (70.5, SD=7.9) years, 70% (52.8%) were female, 67% (68%) were married, 14% (15%)
6 lived alone, 92% (87%) were retired or housewives, 49% (52%) had 6 years of education or above,
7 10% (10%) were on the Comprehensive Social Security Assistance (CSSA) scheme which is open
8 for those with a low income, about half used social media in the last 2 weeks, about 18% (15%)
9 provided care to another (such as their spouse or children/grandchildren), 12% (17%) had drunk
10 alcohol in the past year and 3% (4%) were current smokers. More female patients lived alone, were
11 retired/housewives, had lower education, and had more social security support than male patients
12 (p values < 0.05).

14 Chronic conditions

15 After weighting, overall, the mean number of chronic diseases was 4.1 (SD=1.8) and about one in
16 five patients had 6 or more chronic diseases. The top three chronic conditions were hypertension
17 75%, dyslipidemia (46%), and skeletal and connective tissue inflammation (e.g. arthritis) (36%).
18 The unweighted and weighted prevalence of co-morbidities of the 15 disease categories among the
19 patients is shown in **Figure 2a** and **Figure 2b**, respectively. The unweighted and weighted co-
20 morbidities of top 10 prevalent conditions out of the 43 conditions are shown in **Figure 3a** and
21 **Figure 3b**, respectively, with the combination of hypertension and dyslipidemia being the most
22 common (39% of the patients), followed by hypertension and diabetes mellitus (27%),
23 hypertension and skeletal and connective tissue inflammation (e.g. arthritis) (26%), dyslipidemia
24 and diabetes mellitus (21%), hypertension and chronic pain (20%). Information of the rest co-
25 morbidities is shown in the figures. Female patients had fewer number of chronic conditions, fewer
26 number of medications in use but poorer self-rated health than male patients (p values < 0.05).

28 Biopsychosocial profile and quality of life

29 After weighting, the mean BMI was 24.3 (SD=3.4) with 61% being overweight or obese. Based
30 on the Edmonton Frail Scale, 17% were frail. Eight percent had sarcopenia, 23% reported chewing
31 difficulty, 18% reported incontinence, 36% had stage one or two hypertension currently according

1 to the physical examination, 38% had their handgrip strength (based on the best outcome of two
2 trials of both hands) below the cut-off point, 12% needed help or were dependent in at least one
3 out of the 5 daily functions (using telephone, transportation, shopping, preparing meals, or
4 financial management). Overall, 30%, 59% and 11% of patients rated their health being
5 'excellent/very good/good', 'fair', or 'poor' respectively. Seventy-three percent reported the
6 presence of one (21%) or two or more (52%) body pain areas, 17% scored the HK-MoCA <22
7 suggesting at least mild cognitive impairment; 18% had PHQ-2 ≥ 3 , while 17% had PHQ-9 ≥ 5
8 suggesting mild depression or more severe; 15% had GAD-2 ≥ 3 , while 16% had GAD-7 ≥ 5
9 suggesting mild anxiety or more severe; 50% had insomnia at subthreshold level or above, the
10 mean score of the meaning of existence was 4.9 (SD=1.2) out of 7, 28% reported feeling lonely;
11 the EQ-5D-5L index score was 0.81 (0.20) and its visual analogue scale (VAS) score was 67.6
12 (14.6) out of 100. More finding details can be seen in **Table 2**. More female patients had
13 incontinence, pain, sarcopenia and cognitive impairment than male patients. Female patients were
14 more likely to be screened positive in depression and anxiety, reported severer level of insomnia
15 and reported lower perceived existence of meaning than male patients (p values < 0.05). More
16 male patients used social media. The loneliness level and perceived social support were not
17 significantly different between female and male patients. Female patients were more likely to be
18 frail and have poorer quality of life.

20 **Health service utilization**

21 On average, patients took 2.5 (SD=1.9) medications, with 30% taking 5 or more medications
22 regularly, 36% reported forgot taking medication sometimes. In the last year, 17% were admitted
23 to hospital, 92% attended GOPC, 70% attended SOPC, 10% used elderly day care center services
24 and the median out-of-pocket health cost was 1000 HK\$ (US\$150) for any health expenditures not
25 covered by the public health system or insurance. Male patients reported more GOPC visits than
26 female patients in the past year (p=0.007).

29 **DISCUSSIONS**

30 **Key results**

1 This is one of the few etiological studies on older adults being conducted in Asian primary care
2 settings to examine physical, psychological and social problems accompanying with
3 multimorbidity. The weighted results were in general similar to the unweighted results. The study
4 results were overall in consistency with results reported in the western populations, that
5 biopsychosocial health problems are prominent among the elder adults with multimorbidity in
6 primary care clinics in Hong Kong. Depression, anxiety, insomnia and loneliness were prevalent.
7 Almost one fifth had either depressive or anxiety symptoms, and one quarter reported feeling
8 lonely. Moreover, sleep disturbance appears to be common with almost half reporting significant
9 sleep related symptoms. Some also showed cognition decline with more than one fifth suffered
10 from mild cognitive impairment. In addition, we found that about one quarter of the patients were
11 overweight and another one third were obese, about two thirds of the participants suffered from
12 chronic physical pain involving two body parts, one quarter used 5 or more medications regularly
13 and one third forgot using medications sometimes, one quarter had chewing difficulty, one fifth
14 self-reported incontinence, more than one in ten reported being frail, and some had reduced
15 handgrip strength and signs of sarcopenia. At least one in ten needed help in daily function. Our
16 findings suggest that people with multimorbidity have complex health needs in physical, mental
17 and social aspects such as obesity, multiple body pain, polypharmacy, depression, anxiety,
18 insomnia and loneliness. We showed that in addition to their physical chronic conditions, older
19 adults with multimorbidity were also affected by significant psychological and social problems.

21 **Interpretation**

22 The results suggested that a holistic approach that addresses general physical and functional
23 domain of health, at the same time assessing and managing psychological and social problems is
24 therefore needed in the care of older adults with multimorbidity. The biopsychosocial health
25 problems may interact with each other in determining prognoses. For example, those with
26 depression are less likely to continue with medical treatments for physical problems like diabetes.⁵⁹
27 ⁶⁰ While good social support is a mediator buffering the effects of depression, social isolation and
28 loneliness may lead to worse outcomes both mentally and physically.⁶¹ Existing health services
29 often focus on physical health but neglect the psychosocial aspects of patients. Given the high rates
30 of psychosocial problems reported by patients, services which are designed to cater for the
31 complex needs of elder patients with multimorbidity from biopsychosocial perspectives are

1 urgently needed. These models should also be adapted and tested in local circumstances to
2 maximize its efficacy. Based on these findings, we have been designing and testing a model for
3 tackling biopsychosocial health problems in Hong Kong. In addition, the patients in this study will
4 be followed-up regularly to monitor changes in health status and outcomes by both questionnaire
5 and physical assessments. The first follow-up started in early 2018. The longitudinal
6 biopsychosocial health profiles of these primary care patients will be evaluated, as well as the
7 longitudinal associations of psychosocial factors and multimorbidity, and the impact of
8 biopsychosocial health status on different health outcomes, healthcare use, quality of life and
9 mortality. Furthermore, given the significant differences found between male and female patients
10 in biopsychosocial aspects, future interventions need also to take gender differences into account.

11 12 **Strengths and Limitations**

13 This study has several strengths. First, it covers a range of biopsychosocial factors which are not
14 included in other previous large-scale studies since plenty of them are derived from extracted
15 medical or insurance records. Second, this is one of the very few studies based on Chinese primary
16 care patients with multimorbidity. Third, because it contains linked electronic medical records, it
17 will allow us to follow them up for mortality and public medical service use. Fourth, the results
18 were weighted according to the census data to make the sample more representative of the general
19 population.

20 There are also several limitations. First, self-selection bias might still exist which was
21 consistent with other similar studies,⁶² although we used weighting for adjustment, as not all
22 variables were available for weighting such as education. Since only ambulatory adults who agreed
23 to join were recruited and these usually are more likely to be female and those with higher
24 educational level and higher self-motivation, and those who were house-bound or institutionalized
25 are less likely to have been included, we might have resulted in a relatively healthier and higher-
26 functioning patients in primary care, and the real health status might be worse than what are
27 reported in our study. Future studies may need to take measures to increase participation from
28 male and vulnerable patients. Second, the sample size may limit examinations of potential
29 interactions and factors associated with multimorbidity in some subgroups such as older men and
30 people with lower educational levels, or uncommon health problems among these patients. Third,
31 we used a two-step assessment for some health indicators. While false negative reported rates of

1
2
3 1 pain, insomnia and alcohol use were unlikely, there might be false negative rates for depression
4 and anxiety as the specificity and sensitivity of PHQ-2 and GAD-2 were not 100% (although
5 results from meta-analytic reviews suggest they are reasonable to use in initial screening).^{63 64} In
6 addition, as PHQ-2 and GAD-2 are often used for screening with results in dichotomies
7 (negative/positive), this might limit application of some statistical analysis such as using growth
8 models in future longitudinal data. Fourth, for a few assessments, we only conducted them among
9 a subgroup of participants, e.g. PASE for physical activity among those patients with pain.
10 Furthermore, some additional assessments such as meaning, sarcopenia, oral health were added at
11 a later stage. So only subgroup data could be reported in this paper or analyzed in the future when
12 using these data.
13
14
15
16
17
18
19
20
21

22 **Generalizability**

23 We might have resulted in a relatively healthier sample. After weighting according to age, gender
24 and marital status based on the most recent census data in Hong Kong, the weighted results might
25 be an underestimation of the real situation among elder primary care patients and be more
26 representative of the situation of the older adults of the general population. The rates of health
27 problems reported in our study might be an underestimation of the real situation among the elder
28 primary care patients with multimorbidity in Hong Kong. Future analysis will need to consider
29 this in the interpretation of findings.
30
31
32
33
34
35
36
37

38 **Data availability statement**

39 Data will be available upon reasonable request. The authors warmly welcome collaborations for
40 future research based on this study. For those who would like to request for the data or propose
41 new assessments into the follow-up assessments, they can email to:
42 [yeungshanwong@cuhk.edu.hk].
43
44
45
46
47
48
49

50 **Reference**

- 51 1. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20
52 years. *The European journal of general practice* 2008;14 Suppl 1:28-32. doi:
53 10.1080/13814780802436093 [published Online First: 2008/10/31]
54
55
56
57

- 1 2. Pefoyo AJ, Bronskill SE, Gruneir A, et al. The increasing burden and complexity of multimorbidity.
2 *BMC public health* 2015;15:415. doi: 10.1186/s12889-015-1733-2 [published Online First:
3 2015/04/24]
- 4 3. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of
5 multimorbidity in primary care: A systematic review of observational studies: PLoS ONE. 9 (7) ,
6 2014. Article Number: e102149. Date of Publication: 21 Jul 2014. 2014.
- 7 4. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the
8 literature. *Ageing Res Rev* 2011;10(4):430-9. doi: 10.1016/j.arr.2011.03.003 [published Online
9 First: 2011/03/16]
- 10 5. Salisbury C. Multimorbidity: Time for action rather than words: British Journal of General Practice. 63
11 (607) (pp 64-65), 2013. Date of Publication: February 2013. 2013.
- 12 6. Picco L, Achilla E, Abdin E, et al. Economic burden of multimorbidity among older adults: impact on
13 healthcare and societal costs. *Bmc Health Serv Res* 2016;16 doi: ArtN 173
14 10.1186/S12913-016-1421-7
- 15 7. Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and its effect
16 on health care utilization and cost. *Family practice* 2011;28(5):516-23. doi:
17 10.1093/fampra/cmr013
- 18 8. Organization WH. The global burden of disease: 2004 update. 2008, 2011.
- 19 9. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs)
20 for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and
21 territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*
22 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X
- 23 10. Salisbury C. Multimorbidity: Redesigning health care for people who use it: The Lancet. 379 (9836)
24 (pp 7-9), 2012. Date of Publication: July 2012. 2012.
- 25 11. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort Profile: The Epidemiology of
26 Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. *Int J Epidemiol*
27 2018;47(2):382-84f. doi: 10.1093/ije/dyx259
- 28 12. Hanlon P, Nicholl BI, Jani BD, et al. Frailty and pre-frailty in middle-aged and older adults and its
29 association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank
30 participants, 2018.
- 31 13. Wei MY, Kabeto MU, Galecki AT, et al. Physical Functioning Decline and Mortality in Older Adults
32 with Multimorbidity: Joint Modeling of Longitudinal and Survival Data. *Journals of Gerontology*
33 *Series A Biological Sciences & Medical Sciences* 2018;26:26. doi:
34 <https://dx.doi.org/10.1093/gerona/gly038>
- 35 14. Ibarra-Castillo C, Guisado-Clavero M, Violan-Fors C, et al. Survival in relation to multimorbidity
36 patterns in older adults in primary care in Barcelona, Spain (2010-2014): a longitudinal study
37 based on electronic health records. *Journal of Epidemiology & Community Health*
38 2018;72(3):185-92. doi: <https://dx.doi.org/10.1136/jech-2017-209984>
- 39 15. Guisado-Clavero M, Roso-Llorach A, López-Jimenez T, et al. Multimorbidity patterns in the elderly:
40 a prospective cohort study with cluster analysis. *Bmc Geriatr* 2018;18(1):16.
- 41 16. Katikireddi SV, Skivington K, Leyland AH, et al. The contribution of risk factors to socioeconomic
42 inequalities in multimorbidity across the lifecourse: a longitudinal analysis of the Twenty-07
43 cohort. *BMC medicine* 2017;15(1):152.
- 44 17. Jensen NL, Pedersen HS, Vestergaard M, et al. The impact of socioeconomic status and
45 multimorbidity on mortality: a population-based cohort study. *Clinical Epidemiology* 2017;9:279-
46 89. doi: 10.2147/Clep.S129415
- 47 18. Walker V, Perret-Guillaume C, Kesse-Guyot E, et al. Effect of Multimorbidity on Health-Related
48 Quality of Life in Adults Aged 55 Years or Older: Results from the SU.VI.MAX 2 Cohort. *PloS*
49 *one* 2016;11(12) doi: ARTN e0169282

- 10.1371/journal.pone.0169282
19. Prior A, Fenger-Gron M, Larsen KK, et al. The Association Between Perceived Stress and Mortality Among People With Multimorbidity: A Prospective Population-Based Cohort Study. *Am J Epidemiol* 2016;184(3):199-210. doi: 10.1093/aje/kwv324
20. Vos R, van den Akker M, Boesten J, et al. Trajectories of multimorbidity: exploring patterns of multimorbidity in patients with more than ten chronic health problems in life course. *Bmc Fam Pract* 2015;16(1):2.
21. Farmer C, Fenu E, O'flynn N, et al. Clinical assessment and management of multimorbidity: summary of NICE guidance. *BMJ: British Medical Journal (Online)* 2016;354
22. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. *International journal of epidemiology* 2018;47(2):382-84f.
23. Gunn JM, Ayton DR, Densley K, et al. The association between chronic illness, multimorbidity and depressive symptoms in an Australian primary care cohort. *Social psychiatry and psychiatric epidemiology* 2012;47(2):175-84. doi: 10.1007/s00127-010-0330-z
24. Mavaddat N, Valderas JM, van der Linde R, et al. Association of self-rated health with multimorbidity, chronic disease and psychosocial factors in a large middle-aged and older cohort from general practice: a cross-sectional study, 2014.
25. Bock J-O, Luppia M, Brettschneider C, et al. Impact of depression on health care utilization and costs among multimorbid patients—results from the multicare cohort study. *PloS one* 2014;9(3):e91973.
26. Calderon-Larranaga A, Hernandez-Olivan P, Gonzalez-Rubio F, et al. Multimorbidity and weight loss in obese primary care patients: Longitudinal study based on electronic healthcare records, 2015.
27. France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: A systematic review of prospective cohort studies, 2012.
28. Boeckxstaens P, Vaes B, Legrand D, et al. The relationship of multimorbidity with disability and frailty in the oldest patients: A cross-sectional analysis of three measures of multimorbidity in the BELFRAIL cohort, 2015.
29. Brettschneider C, Leicht H, Bickel H, et al. Relative impact of multimorbid chronic conditions on health-related quality of life—results from the MultiCare Cohort Study. *PloS one* 2013;8(6):e66742.
30. Mercer SW, Gunn J, Wyke S. Improving the health of people with multimorbidity: the need for prospective cohort studies: SAGE Publications Sage UK: London, England, 2011.
31. France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: a systematic review of prospective cohort studies. *Br J Gen Pract* 2012;62(597):e297-e307.
32. Kuo RN, Lai MS. The influence of socio-economic status and multimorbidity patterns on healthcare costs: a six-year follow-up under a universal healthcare system. *International journal for equity in health* 2013;12:69. doi: 10.1186/1475-9276-12-69
33. Gu J, Chao J, Chen W, et al. Multimorbidity and health-related quality of life among the community-dwelling elderly: A longitudinal study, 2018.
34. Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry, 2018.
35. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. *Age and ageing* 2012;42(1):62-69.
36. Muth C, Beyer M, Fortin M, et al. Multimorbidity's research challenges and priorities from a clinical perspective: The case of 'Mr Curran': *European Journal of General Practice*. 20 (2) (pp 139-147), 2014. Date of Publication: June 2014. 2014.
37. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity is common to family practice: is it commonly researched?: *Canadian family physician Medecin de famille canadien*. 51 (pp 244-245), 2005. Date of Publication: Feb 2005. 2005.

- 1
2
3 1 38. Kadam U. Redesigning the general practice consultation to improve care for patients with
4 2 multimorbidity: BMJ (Online). 345 (7878) , 2012. Article Number: e6202. Date of Publication:
5 3 13 Oct 2012. 2012.
- 6 4 39. Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of
7 5 interventions in primary care and community settings. *Bmj* 2012;345:e5205.
- 8 6 40. Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. *Bmj*
9 7 2015;350(176):10.1136.
- 10 8 41. The Government of Hong Kong Special Administrative Region. 2016 Population By-census.
11 9 <http://wwwbycensus2016govhk/en/bc-mthtml> 2018;Accessed on July 31, 2018
- 12 10 42. Centre for Health Protection DoH, The Government of the Hong Kong Special Administrative
13 11 Region, . Life Expectancy at Birth (Male and Female), 1971 - 2017
14 12 <https://wwwchpgovhk/en/statistics/data/10/27/111html> 2018;Availabe on July 23 2018
- 15 13 43. Hospital Authority HKS. Hospital Authority Annual Report 2016-2017.
16 14 <http://wwwhaorghk/ho/corpcomm/AR201617/ebook/en/mobile/indexhtml#p=1> 2018
- 17 15 44. Wang HH, Wang JJ, Wong SY, et al. Epidemiology of multimorbidity in China and implications for
18 16 the healthcare system: cross-sectional survey among 162,464 community household residents in
19 17 southern China. *BMC Med* 2014;12:188. doi: 10.1186/s12916-014-0188-0 [published Online
20 18 First: 2014/10/24]
- 21 19 45. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health
22 20 care, research, and medical education: a cross-sectional study. *Lancet* 2012;380(9836):37-43. doi:
23 21 10.1016/S0140-6736(12)60240-2 [published Online First: 2012/05/15]
- 24 22 46. Yu XN, Stewart SM, Wong PTK, et al. Screening for depression with the Patient Health
25 23 Questionnaire-2 (PHQ-2) among the general population in Hong Kong. *Journal of Affective*
26 24 *Disorders* 2011;134(1-3):444-47. doi: 10.1016/j.jad.2011.05.007
- 27 25 47. Yu X, Tam WW, Wong PT, et al. The Patient Health Questionnaire-9 for measuring depressive
28 26 symptoms among the general population in Hong Kong. *Comprehensive psychiatry*
29 27 2012;53(1):95-102.
- 30 28 48. Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a
31 29 systematic review and diagnostic metaanalysis. *General hospital psychiatry* 2016;39:24-31.
- 32 30 49. Leung GT, de Jong Gierveld J, Lam LC. Validation of the Chinese translation of the 6-item De Jong
33 31 Gierveld Loneliness Scale in elderly Chinese. *International psychogeriatrics* 2008;20(6):1262-72.
34 32 doi: 10.1017/S1041610208007552
- 35 33 50. Doris S. Insomnia Severity Index: psychometric properties with Chinese community-dwelling older
36 34 people. *Journal of advanced nursing* 2010;66(10):2350-59.
- 37 35 51. Ngai SP, Cheung RT, Lam PL, et al. Validation and reliability of the Physical Activity Scale for the
38 36 Elderly in Chinese population. *Journal of rehabilitation medicine* 2012;44(5):462-65.
- 39 37 52. Rolfson DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton Frail Scale.
40 38 *Age and ageing* 2006;35(5):526-29.
- 41 39 53. Zhang D, Chan DC-C, Niu L, et al. Meaning and its association with happiness, health and healthcare
42 40 utilization: A cross-sectional study. *Journal of affective disorders* 2018;227:795-802.
- 43 41 54. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. *Journal*
44 42 *of the American Medical Directors Association* 2013;14(8):531-32.
- 45 43 55. Woo J, Leung J, Morley JE. Validating the SARC-F: A suitable community screening tool for
46 44 sarcopenia? *Journal of the American Medical Directors Association* 2014;15(9):630-34.
- 47 45 56. Wong A, Xiong YY, Kwan PW, et al. The validity, reliability and clinical utility of the Hong Kong
48 46 Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease.
49 47 *Dementia and geriatric cognitive disorders* 2009;28(1):81-87.
- 50 48 57. Wong EL, Ramos-Goñi JM, Cheung AW, et al. Assessing the Use of a Feedback Module to Model
51 49 EQ-5D-5L Health States Values in Hong Kong. *The Patient-Patient-Centered Outcomes*
52 50 *Research* 2018;11(2):235-47.
- 53
54
55
56
57
58
59
60

- 1
2
3 1 58. Census and Statistics Department (C&SD) of Hong Kong SAR. Interactive Data Dissemination
4 2 Service for the 2016 Population By-census. https://wwwbycensus2016govhk/en/bc-own_tblhtml
5 3 2016 (Available on May 18, 2019)
6 4 59. Lustman PJ, Clouse RE. Treatment of depression in diabetes: impact on mood and medical outcome.
7 5 *Journal of psychosomatic research* 2002;53(4):917-24. [published Online First: 2002/10/16]
8 6 60. Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of
9 7 chronic diseases in the United States: a meta-analysis. *Journal of general internal medicine*
10 8 2011;26(10):1175-82. doi: 10.1007/s11606-011-1704-y [published Online First: 2011/05/03]
11 9 61. Uchino BN. Social support and health: a review of physiological processes potentially underlying
12 10 links to disease outcomes. *J Behav Med* 2006;29(4):377-87. doi: 10.1007/s10865-006-9056-5
13 11 [published Online First: 2006/06/08]
14 12 62. Silva Junior SH, Santos SM, Coeli CM, et al. Assessment of participation bias in cohort studies:
15 13 systematic review and meta-regression analysis. *Cad Saude Publica* 2015;31(11):2259-74. doi:
16 14 10.1590/0102-311X00133814 [published Online First: 2016/02/04]
17 15 63. Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a
18 16 systematic review and diagnostic metaanalysis. *General hospital psychiatry* 2016;39:24-31. doi:
19 17 10.1016/j.genhosppsy.2015.11.005 [published Online First: 2016/01/01]
20 18 64. Mitchell AJ, Yadegarfar M, Gill J, et al. Case finding and screening clinical utility of the Patient
21 19 Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-
22 20 analysis of 40 studies. *BJPsych Open* 2016;2(2):127-38. doi: 10.1192/bjpo.bp.115.001685
23 21 [published Online First: 2016/10/06]
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Table 1 Core topic areas in questionnaires and examinations of the study

Assessment	Description
<i>Questionnaire</i>	
Use of medication	number and duration (0-1 year/2-5 years/>5 years) for antihypertensive, cardiovascular and hypolipidemic drugs, antidiabetics, antipsychotics and analgesics
Compliance of medication use	“At times, do you forget to take your prescription medications?” (no/yes)
Depression	The 2-item Patient Health Questionnaire (PHQ-2) for depression; The 9-item Patient Health Questionnaire (PHQ-9) for those with PHQ-2 \geq 3
Anxiety	The 2-item Generalised Anxiety Disorder (GAD-2); The 7-item Generalised Anxiety Disorder (GAD-7) for those with GAD-2 \geq 3
Loneliness*	De Jong Gierveld Loneliness Scale; and one question asking “Do you feel lonely? (Yes/No)” (added at a later stage)
Insomnia	The 7-item Insomnia Severity Index (ISI) for those answered yes to the screening question “In the past two weeks, do you have insomnia? (Yes/No)”
Pain	A screening question of “In the past year, do you have musculoskeletal pain for at least 3 months”, for those who answered ‘yes, one pain area or ‘yes, two or more pain areas’, Brief Pain Inventory (BPI) was measured.
Physical activity	For those were screened positive in pain, Physical Activity Scale for the Elderly (PASE) was measured
Self-rated health	“In general, how will you describe your health? (extremely good, very good or good/fair/poor)
Community network	“When you need help, do you have someone who is willing to and able to meet your needs?” (always/sometimes/never)
Meaning of existence*	One item extracted from the validated reliable Chinese Purpose in Life test (CPIL)
Use of social media	A screening question of “In the past two weeks, have you ever used the following social media”, for those who answered yes to any of the social media, they were further assessed with importance and comfort of using internet.
Oral health*	“Do you have any difficulty when biting or chewing foods (even with the use of denture)” (yes/no)
Incontinence*	“Do you have incontinence?” (yes/occasionally/no)
Frailty*	The Edmonton Frail Scale

Sarcopenia*	The 5-item Sarcopenia Assessment (SARC-F)
Cognition	Mainly assessed with Montreal Cognitive Assessment Hong Kong version (HK-MoCA) but in an earlier stage, Abbreviated Memory Inventory for Chinese (AMIC) was used.
Quality of life	The EuroQol EQ-5D-5L (EQ5D)
Daily Function	Instrumental Activities of Daily Living (IADL) including ability to use telephone, mode of transportation, shopping, food preparation, ability to handle finances
Use of health services	Visits to primary care doctors, specialist outpatient clinics, admission to hospital, use of services in elderly daycare centers and out-of-pocket healthcare cost both in private and public in the past year
Alcohol use	The 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C) for those who drank alcohol in the past year
Tobacco use	One question asking for current, ex- and non-smoking behavior
Caregiving to somebody else	“Are you taking care of somebody?” (Yes/No)
Social economic status	Age, gender, marriage, living status, employment, receiving of social welfare scheme
<u>Physical examination</u>	
Blood pressure	Measured twice in 15 minutes after rest
Body Mass Index (BMI)	
Waist circumference	
Handgrip strength	Each hand was measured twice
<u>Electronic health record and self-report data</u>	
Chronic diseases	43 common chronic conditions in 15 categories including: <ol style="list-style-type: none"> 1. Metabolic diseases (hypertension, lipid disorder, diabetes) 2. Cancer 3. Disease of the cardiovascular system (coronary heart disease, stroke/cerebrovascular disease, peripheral vascular disease) 4. Disease of the respiratory system (COPD, bronchiectasis, asthma, chronic pharyngitis /laryngitis) 5. Disease of the liver, spleen and gallbladder (gallbladder/spleen disease, viral hepatitis, chronic liver disease) 6. Disease of the stomach and intestines (dyspepsia and gastritis, diverticular disease of intestine, chronic enteritis; irritable bowel syndrome; constipation)

7. Disease of the musculoskeletal and connective tissue (chronic pain needing medication control, skeletal and connective tissue inflammation (such as arthritis, gout))
8. Disease of the genitourinary system (chronic kidney disease (nephritis), prostatitis, benign prostatic hyperplasia)
9. Disease of the ear, nose and throat (ENT) (chronic rhinitis, deafness/tinnitus)
10. Disease of the visual system (glaucoma/cataracts, blindness/amblyopia, diabetic eyes, retinal detachment)
11. Disease of the skin (eczema, psoriasis)
12. Disease of the blood (anemia)
13. Disease of the nervous system (multiple sclerosis, migraine, epilepsy, Parkinson's disease)
14. Mental disorders (schizophrenia/bipolar disorder, depression, anxiety & other stress related disorders, dementia)
15. Others

Use of medication

Medication use number and duration (0-1 year/2-5 years/>5 years) for antihypertensive drugs, cardiovascular drugs, cholesterol-lowering drugs, antidiabetics, antipsychotics and analgesics

* Measures were added at later stages: about 712 to 995 patients received these measures.

1
2
3

Table 2 Basic characteristics and biopsychosocial health profile of the elderly with multimorbidity in primary care in Hong Kong

Characteristics	Un-weighted rates and analyses				Weighted rates and analyses			
	Female (n = 753)	Male (n = 324)	P values	Crude total %	Female (n = 568)	Male (n = 508)	P values	Weighted total %
Female				69.9%				52.8%
Age (mean, sd)	69.6 (6.6)	71.1 (7.1)	<0.001	70.0 (6.8)	71.3 (8.4)	70.2 (7.9)	0.097	70.5 (7.9)
60-64	22.8%	19.8%	0.002	22.0%	28.8%	31.4%		30.2%
65-69	35.6%	26.5%		32.9%	22.9%	25.3%		24.0%
70-74	21.8%	24.4%		22.5%	12.5%	14.5%		13.4%
75-79	9.7%	16.4%		11.6%	12.1%	13.0%		12.5%
80 or above	10.1%	13.0%		11.0%	23.8%	15.7%		20.0%
Marriage			<0.001				<0.001	
married	57.9%	89.2%		67.3%	54.7%	82.9%		68.1%
single/divorced/separated	11.8%	4.3%		9.6%	10.9%	9.6%		10.3%
widowed	30.2%	6.5%		23.1%	34.4%	7.5%		21.7%
No. of children (mean, sd)	2.5 (1.6)	2.5 (1.2)	0.409	2.52 (1.47)	2.7 (1.9)	2.4 (1.3)	0.013	2.53 (1.6)
Living alone	16.5%	8.3%	<0.001	14.0%	18.4%	11.9%	0.004	14.6%
Employment								
Retired/ Housewife	96.0%	82.4%	<0.001	91.9%	95.8%	77.5%	0.000	86.9%
Employed	4.0%	17.6%		8.1%	4.2%	22.5%		13.1%
Education (year, mean, sd)	7.2 (4.7)	8.7 (4.1)	<0.001	7.7 (4.6)	6.5 (4.6)	8.9 (4.1)	<0.001	7.7 (4.5)
Year of education \geq 6 years	46.8%	59.5%	0.001	49.3%	40.7%	63.2%	<0.001	51.8%
Social security recipient	58.1%	59.3%	0.726	58.6%	59.8%	50.5%	0.002	55.4%
Comprehensive Social Security Assistance (CSSA) Scheme	11.4%	7.1%	0.031	10.1%	12.3%	7.6%	0.011	10.1%
Fruit Voucher	44.7%	50.3%	0.089	46.4%	45.5%	41.5%	0.190	43.6%
Disability allowance	3.7%	3.1%	0.604	3.5%	3.9%	3.0%	0.426	3.5%
Other	0.5%	0.3%	0.621	0.5%	0.4%	0.3%	0.803	0.3%
Caregiving to somebody	18.9%	14.5%	0.118	17.6%	16.8%	13.0%	0.126	15.0%
Alcohol use								
Yes, in last 12 months	5.4%	29.3%	<0.001	12.6%	5.2%	29.8%	<0.001	16.8%
AUDIT-C [§]								
AUDIT-C positive (\geq 3)	1.4%	11.1%	<0.001	4.4%	1.5%	11.2%	<0.001	6.1%
Smoke			<0.001				<0.001	
Never smoke	97.1%	60.5%		86.1%	96.9%	60.3%		79.6%
Smoke	0.8%	7.1%		2.7%	0.8%	7.2%		3.8%
Quit smoke	2.1%	32.4%		11.2%	2.4%	32.5%		16.6%
Self-rated health							0.001	

1									
2									
3	Excellent/very good/good	26.0%	34.7%	<0.001	28.5%	26.8%	32.7%		29.5%
4	Fair	59.5%	58.4%		59.2%	58.6%	60.1%		59.3%
5	Poor	14.6%	6.9%		12.3%	14.7%	7.2%		11.2%
6	Number of chronic conditions (mean, sd)	4.0 (1.7)	4.3 (1.9)	0.004	4.1 (1.8)	4.0 (1.7)	4.3 (1.9)	0.026	4.1 (1.8)
7	2 diseases	21.4%	15.4%	0.003	19.6%	22.6%	16.0%	0.019	19.4%
8	3 diseases	25.5%	28.7%		26.5%	25.1%	29.8%		27.3%
9	4 diseases	21.0%	17.0%		19.8%	19.5%	16.1%		17.9%
10	5 disease	15.0%	13.0%		14.4%	14.8%	12.7%		13.8%
11	6+ disease	17.1%	25.9%		19.8%	18.1%	25.4%		21.5%
11	Chronic conditions by category								
12	Metabolic diseases	82.2%	86.7%	0.066	83.6%	83.8%	85.5%	0.449	84.6%
13	Cancer	7.3%	13.0%	0.003	9.0%	7.0%	11.6%	0.009	9.2%
14	Cardiovascular diseases (CVD)	13.4%	24.7%	<0.001	16.9%	14.5%	24.1%	<0.001	19.0%
15	Respiratory disease	6.1%	9.6%	0.043	7.2%	6.4%	9.9%	0.039	8.1%
16	Liver disease	9.3%	10.2%	0.649	9.6%	9.3%	10.8%	0.439	10.0%
17	Gastrointestinal disorders	28.0%	23.8%	0.148	26.7%	27.7%	23.2%	0.093	25.5%
18	Musculoskeletal disorders (MSK)	65.2%	48.8%	<0.001	60.3%	65.5%	49.8%	<0.001	58.1%
19	Thyroid disease	9.7%	1.9%	<0.001	7.3%	9.2%	1.9%	<0.001	5.7%
20	Renal disease	2.3%	33.3%	<0.000	11.6%	2.1%	31.7%	<0.001	16.1%
21	ENT	8.9%	9.3%	0.849	9.0%	8.8%	9.6%	0.645	9.2%
22	Eye	27.9%	22.5%	0.067	26.3%	29.1%	20.5%	0.001	25.0%
23	Skin	9.3%	9.9%	0.765	9.5%	9.0%	10.5%	0.401	9.7%
24	Anemia	3.1%	2.8%	0.806	3.0%	3.0%	2.8%	0.867	2.9%
25	Neurological disease	0.7%	1.2%	0.346	0.8%	0.5%	1.3%	0.175	0.9%
26	Mental disorders	16.7%	10.2%	0.005	14.8%	16.4%	11.2%	0.015	14.0%
27	Use of medication								
28	Antihypertensive drugs (mean, sd)	1.0 (0.9)	1.2 (0.9)	0.082	1.1 (0.9)	1.1 (0.9)	1.1 (0.9)	0.431	1.1 (0.9)
29	Percentage of patients who use	69.1%	75.3%	0.038	70.9%	71.3%	74.0%	0.326	72.5%
30	Cardiovascular drugs (mean, sd)	0.2 (0.5)	0.3 (0.6)	<0.001	0.2 (0.5)	0.2 (0.5)	0.3 (0.7)	0.024	0.24 (0.6)
31	Percentage of patients who use	11.8%	22.8%	<0.001	15.1%	12.7%	21.8%	<0.001	17.0%
32	Antidiabetics (mean, sd)	0.4 (0.7)	0.5 (0.8)	0.0195	0.4 (0.8)	0.3 (0.7)	0.5 (0.8)	0.029	0.4 (0.7)
33	Percentage of patients who use	22.6%	31.8%	0.001	25.4%	22.1%	31.9%	<0.001	26.7%
34	Cholesterol-lowering drugs (mean, sd)	0.4 (0.5)	0.5 (0.5)	0.005	0.4 (0.5)	0.4 (0.5)	0.5 (0.5)	0.004	0.4 (0.5)
35	Percentage of patients who use	38.8%	48.2%	0.004	41.6%	37.5%	48.4%	<0.001	42.7%
36	Antipsychotics (mean, sd)	0.2 (0.8)	0.1 (0.5)	0.038	0.2 (0.7)	0.2 (0.8)	0.1 (0.5)	0.035	0.2 (0.7)
37	Percentage of patients who use	11.7%	7.4%	0.035	10.4%	11.1%	7.7%	0.055	9.5%
38	Analgesics (mean, sd)	0.1 (0.5)	0.1(0.4)	0.875	0.1 (0.5)	0.1 (0.5)	0.1 (0.4)	0.929	0.1 (0.4)
39	Percentage of patients who use	10.5%	10.8%	0.879	10.6%	9.8%	10.2%	0.833	10.0%
40	Total number of medication (mean, sd)	2.3 (1.9)	2.7 (1.9)	0.001	2.4 (1.9)	2.3 (1.9)	2.6 (1.9)	0.025	2.5 (1.9)
41	% forgetting taking medication (n=995)	38.4%	34.0%	0.196	37.1%	36.3%	34.8%	0.640	35.6%
42	Oral Health Problem (n=992)	25.3%	20.6%	0.119	23.9%	24.8%	20.5%	0.104	22.8%
43	Incontinence (n=992)			0.004				<0.001	
44	No	77.0%	86.3%		79.7%	76.9%	86.6%		81.5%
45	Occasionally	21.3%	12.7%		18.8%	20.3%	12.7%		16.7%
46	Yes	1.7%	1.0%		1.5%	2.8%	0.7%		1.8%
47									

Pain									
Muscle-skeletal pain for at least 3 months in the past year			0.000				<0.001		
	No	19.1%	37.7%		24.9%	18.7%	37.4%	27.5%	
	Yes, one pain area	19.7%	23.8%		10.9%	18.7%	23.6%	21.0%	
	Yes, two or more pain areas	61.2%	38.6%		64.3%	62.7%	39.0%	51.5%	
Brief Pain Inventory (BPI) ^c									
	Interference (n=809)	4.6 (1.9)	4.1 (1.9)	<0.001	4.5 (1.9)	4.7 (2.0)	4.1 (1.9)	<0.001	4.4 (2.0)
	Severity (n=810)	2.9 (2.2)	2.2 (1.8)	<0.001	2.7 (2.1)	2.9 (2.2)	2.2 (1.8)	<0.001	2.6 (2.1)
Physical Activity Scale for the Elderly (PASE) (n=809) ^d									
	Mean (SD)	77.4 (34.9)	89.1 (61.5)	<0.001	80.3 (43.4)	74.7 (36.1)	95.7 (67.3)	<0.001	83.3 (52.2)
Sarcopenia (mean, sd) (n=719) ^f									
	Positive (≥4)	11.0%	5.7%	0.019	9.3%	15.5%	5.1%	<0.001	10.4%
	Negative (0-3)	89.0%	94.3%		90.7%	84.5%	94.9%		89.6%
Cognition ^h									
	AMIC (mean, sd) (n=337)	2.2 (1.7)	1.7 (1.6)	0.035	2.1 (1.7)	2.1 (1.7)	1.6 (1.6)	0.038	1.9 (1.7)
	AMIC Positive % (≥3)	40.6%	27.3%	0.027	37.1%	39.3%	24.7%	0.007	33.3%
	HK-MOCA (n=785)	24.7 (4.3)	25.4 (3.2)	0.026	24.9 (4.0)	24.0 (4.8)	25.5 (3.1)	<0.001	24.7 (4.1)
	HK-MOCA Abnormal % (<22)	17.5%	12.6%	0.080	15.9%	23.0%	10.5%	<0.001	16.9%
Depression									
	PHQ-2	1.3 (1.6)	0.8 (1.2)	<0.001	1.2 (1.5)	1.3 (1.6)	0.8 (1.3)	<0.001	1.1 (1.5)
	Screen (-) (<3)	78.1%	88.3%	<0.001	81.2%	77.8%	87.6%	<0.001	82.4%
	Screen (+) (≥3)	21.9%	11.7%		18.9%	22.2%	12.4%		17.6%
	PHQ-9 (mean, sd) ^a	11.4 (4.3)	10.5 (4.5)	0.274	11.2 (4.4)	11.4 (4.2)	10.4 (4.3)	0.179	11.0 (4.3)
	Mild (5-9)	8.8%	4.3%		7.4%	8.6%	4.8%		6.8%
	Moderate (10-14)	7.3%	4.9%		6.6%	8.2%	5.4%		6.9%
	Moderately severe (15-19)	4.2%	1.2%		3.3%	4.0%	1.2%		2.7%
	Severe (20+)	1.3%	0.9%		1.2%	1.2%	0.8%		1.0%
Anxiety									
	GAD-2 (≥3) (mean, sd)	1.4 (1.5)	0.8 (1.1)	<0.001	1.2 (1.5)	1.4 (1.6)	0.8 (1.1)	<0.001	1.1 (1.4)
	Screen (-) (<3)	79.7%	91.1%	<0.001	83.0%	79.5%	90.9%	<0.001	84.9%
	Screen (+) (≥3)	20.3%	9.0%		17.0%	20.5%	9.1%		15.1%
	GAD-7 (mean, sd) ^b	10.8 (3.9)	9.8 (3.7)	0.182	10.7 (3.9)	10.9 (3.9)	10.1 (3.6)	0.294	10.7 (3.8)
	Mild (5-9)	0.9%	0.3%		0.7%	0.7%	0.2%		0.5%
	Moderate (10-14)	6.9%	4.6%		6.2%	8.5%	5.0%		6.8%
	Moderately Severe (15-19)	9.6%	3.4%		7.7%	10.1%	4.4%		7.4%
	Severe (20+)	2.9%	0.6%		2.2%	3.6%	0.6%		2.2%
Insomnia									
Insomnia in the past 2 weeks			0.030					0.086	
	No	31.5%	28.3%		33.5%	32.2%	37.2%	34.6%	
	Yes	68.5%	61.7%		66.5%	67.8%	62.8%	65.4%	

1									
2									
3	ISI (n=716) (mean, sd) ^e	12.0 (5.1)	10.2 (4.6)	<0.001	11.5 (5.0)	11.9 (5.1)	10.1 (4.5)	<0.001	11.1 (4.9)
4	No clinically significant insomnia (0-7)	13.7%	18.2%		15.0%	14.2%	18.8%		16.4%
5	Subthreshold insomnia (8-14)	31.1%	29.0%		30.5%	31.0%	29.7%		30.4%
6	Clinical insomnia, moderate severity (15-21)	22.2%	14.2%		19.8%	22.1%	15.0%		18.8%
7	Clinical insomnia, severe (22-28)	1.6%	0.3%		1.2%	1.5%	0.3%		0.9%
8	Meaning (0-7) (n=544)	4.8 (1.2)	5.0 (1.1)	0.098	4.8 (1.2)	4.7 (1.3)	5.0 (1.1)	0.022	4.9 (1.2)
9	Loneliness (n=741)								
10	One question (yes/no)			0.009				0.128	
11	No	68.0%	77.1%		72.5%	69.8%	74.6%		72.2%
12	Yes	32.1%	22.9%		27.5%	30.2%	25.4%		27.9%
13	De Jong Gierveld Loneliness Scale								
14	Total loneliness score (mean, sd)	1.8 (1.9)	1.6 (1.7)	0.121	0.7 (1.2)	1.8 (1.8)	1.6 (1.7)	0.309	1.7 (1.8)
15	Emotional loneliness score (mean, sd)	1.0 (1.1)	0.9 (1.0)	0.156	1.6 (1.8)	0.9 (1.0)	0.9 (1.0)	0.566	0.9 (1.0)
16	Social loneliness score (mean, sd)	0.8 (1.3)	0.7 (1.2)	0.121	0.9 (1.0)	0.8 (1.3)	0.7 (1.3)	0.350	0.8 (1.3)
17	Social Support (can count on someone willing and able to meet your needs)			0.083				0.146	
18	Always	61.2%	66.3%		62.7%	61.6%	65.8%		63.5%
19	Sometimes	31.1%	30.0%		30.7%	31.2%	28.6%		30.0%
20	Never	7.7%	4.1%		6.7%	7.3%	5.6%		6.5%
21	Use of social media in last 2 weeks								
22	Yes	52.5%	52.1%	0.849	52.6%	46.6%	55.8%	0.003	51.0%
23	Web	20.9%	33.6%	<0.001	24.7%	18.5%	36.5%	<0.001	27.0%
24	WhatsApp	51.4%	50.0%	0.675	51.0%	45.9%	52.6%	0.028	49.0%
25	Facebook	15.9%	20.4%	0.077	17.3%	14.5%	20.7%	0.006	17.4%
26	Blog	1.7%	3.4%	0.089	2.2%	1.3%	3.0%	0.065	2.1%
27	E-literacy (n=566) ^e	25.0 (11.7)	24.9 (12.6)	0.931	25.0 (12.0)	25.5 (11.6)	25.4 (12.7)	0.953	25.4 (12.2)
28	Importance of social media (total score: 6-24)	11.3 (4.8)	10.8 (4.7)	0.218	11.1 (4.8)	11.5 (4.7)	10.8 (4.8)	0.171	11.1 (4.8)
29	Comfort of using social media (total score: 3-18)	8.2 (4.5)	8.2 (4.7)	0.975	8.2 (4.5)	8.3 (4.4)	8.3 (4.7)	0.878	8.3 (4.5)
30	Daily function (Percentage of patients needing help or being dependent)								
31	Total	8.4%	14.8%	0.001	10.3%	10%	14.3%	0.056	12.3%
32	Using telephone	0.7%	1.2%		0.8%	1%	1%		1%
33	Transportation	4.7%	5.6%		4.3%	5.9%	5.4%		5.7%
34	Shopping	5.7%	5.0%		5.5%	7.5%	4.8%		6.2%
35	Preparing meals	4.3%	12.7%		6.8%	5.5%	12.7%		8.9%
36	Financial management	2.9%	4.9%		3.5%	4.1%	0.9%		2.6%
37	Frailty								
38	Edmonton Frail Scale (EFS) (mean, sd) (n=989) ^f	3.5 (2.3)	3.1 (2.0)	0.003	3.4 (2.2)	3.7 (2.4)	3.1 (2.0)	<0.001	3.4 (2.2)
39	No frailty (0-5)	80.3%	88.3%	0.012	82.6%	77.6%	88.7%	<0.001	82.8%
40	Apparently vulnerable (6-7)	13.7%	8.6%		12.2%	13.8%	8.7%		11.4%
41	Mild frailty (8-9)	4.7%	2.4%		4.0%	6.8%	2.0%		4.6%
42	Moderate frailty (10-11)	1.3%	0.3%		1.0%	1.8%	0.2%		1.1%

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Severe frailty (12-18)	0%	0.33%		0.1%		0%	0.4%		0.2%
Quality of life (EQ5D-5L)									
Index score (range: -0.864 to 1)	0.8 (0.2)	0.9 (0.2)	0.001	0.81 (0.20)		0.8 (0.2)	0.9 (0.2)	<0.001	0.81 (0.2)
visual analogue scale (VAS) (0-100)	66.0 (15.3)	69.6 (13.4)	<0.001	67.1 (14.8)		66.0 (15.4)	69.4 (13.3)	0.001	67.6 (14.6)
Health care utilization in the past year									
Hospitalization frequency									
			0.453					0.557	
0	83.8%	81.2%		83.0%		83.6%	82.0%		82.9%
1-2	14.4%	17.3%		15.2%		14.0%	16.7%		15.3%
2+	1.9%	1.5%		1.8%		2.4%	1.3%		1.9%
Hospitalization Length (days, mean, sd) (n=1073)	1.1 (5.1)	1.5 (8.2)	0.424	1.2 (6.2)		1.1 (5.1)	1.4 (8.3)	0.535	1.2 (6.8)
Specialist Out-patient Clinics (SOPC)	69.0%	70.7%	0.587	69.5%		68.8%	70.2%	0.636	69.5%
General Out-patient Clinics (GOPC)	89.6%	94.1%	0.018	91.0%		89.8%	94.3%	0.007	92.0%
Elderly day care service	9.4%	9.9%	0.824	9.6%		10.2%	9.1%	0.554	9.6%
Cost (out of pocket) (HKD) median (interquartile range, IQR) (n=1063)	1000 (0, 3000)	1000 (0, 2000)	0.141	1000 (0, 3000)		1000 (0, 3000)	1000 (0, 2000)	0.488	1000 (0, 3000)
Physical examinations									
Blood pressure (BP)									
Systolic (mean, sd)	133.2 (15.6)	134.2 (15.9)	0.337	133.5 (15.7)		133.5 (16.3)	133.3 (15.2)	0.848	133.4 (15.8)
Diastolic (mean, sd)	74.9 (9.6)	78.4 (10.0)	<0.001	75.9 (9.9)		74.1 (10.0)	78.6 (9.9)	<0.001	76.2 (10.2)
Normal (SBP <120 & DBP <80)	19.2%	14.8%	0.272	17.9%		19.9%	15.8%	0.070	17.9%
Pre-hypertension (SBP: 120-139 or DBP: 80-89)	45.8%	48.2%		46.5%		44.6%	48.4%		46.4%
Stage I hypertension (SBP: 140-159 or DBP: 90-99)	30.2%	30.6%		30.3%		29.9%	29.8%		29.8%
Stage II hypertension (SBP ≥ 160 or DBP ≥ 100)	4.8%	6.5%		5.3%		5.6%	6.0%		5.8%
Pulse (per minute)	71.5 (19.5)	75.2 (28.0)	0.016	72.7 (22.5)		71.7 (22.0)	74.9 (24.8)	0.041	73.2 (23.4)
Weight (kg, mean, sd)	57.5 (56.8)	66.5 (9.6)	<0.001	60.2 (10.4)		56.9 (9.3)	66.9 (9.7)	<0.001	61.6 (10.7)
Height (cm, mean, sd)	154.0 (6.2)	165.5 (6.7)	<0.001	157.4 (8.2)		153.4 (6.2)	165.6 (6.7)	<0.001	159.2 (8.8)
Waist circumference (cm, mean, sd)	88.8 (9.7)	93.2 (9.5)	<0.001	90.2 (9.9)		89.1 (9.9)	93.2 (9.2)	<0.001	91.1 (9.8)
Body mass Index (BMI) (mean, sd)	24.2 (3.8)	24.2 (2.0)	0.963	24.2 (3.6)		24.2 (3.7)	24.4 (3.1)	0.398	24.3 (3.4)
Underweight (<18.5)	4.1%	2.8%	0.067	3.7%		3.6%	2.7%	0.013	3.1%
Normal (18.5-22.9)	37.6%	31.3%		35.7%		38.9%	31.5%		35.4%
Overweight (23-24.9)	20.4%	26.0%		22.1%		20.5%	23.6%		22.0%
Obese (≥ 25)	37.9%	39.9%		38.5%		37.0%	42.2%		39.5%
Handgrip strength (kg) ⁱ									
< cutoff score (<26 for male, <18 for female)	36.3%	36.1%	0.964	36.2%		40.2%	34.7%	0.061	37.6%

Left hand (mean, sd)	17.4 (4.2)	26.4 (7.0)	20.1 (6.6)	17.0 (4.2)	26.7 (7.0)	21.5 (7.5)
Right hand (mean, sd)	18.5 (4.3)	27.4 (7.5)	21.1 (6.8)	18.0 (4.3)	27.5 (7.7)	22.5 (7.7)
Both hand (mean, sd)	19.1 (4.1)	28.5 (7.1)	21.9 (6.7)	18.6 (4.0)	28.8 (7.2)	23.4 (7.6)

Abbreviations: GAD-2: the two-item General Anxiety Disorder scale; HK-MoCA: Montreal Cognitive Assessment Hong Kong version (HK-MoCA); ISI: the 7-item Insomnia Severity Index; EQ5D: the EuroQol EQ-5D-5L; PHQ-2: The two item Patient Health Questionnaire for depression; The 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C); SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure.

Notes:

^a Mean (SD) was for 203 patients who did PHQ-9. The % was for all the 1077 patients with the rest 874 patients who screened negative in PHQ-2 regarded as having normal scores in PHQ-9.

^b Mean (SD) was for 182 patients who did GAD-7. The % was for all the 1077 patients with the rest 895 patients who screened negative in GAD-2 regarded as having normal scores in GAD-7.

^c 719 patients were assessed with ISI.

^d Only those who had one or more pain areas in the past 3 months were assessed with BPI or PASE-C.

^e Only those who had social media use in the past 2 weeks were assessed.

^f Measured by the 5-item Sarcopenia Assessment (SARC-F) which were added at a later stage.

^g N=136, those who did not drink alcohol the past 12 months were regarded as 0 in AUDIT-C.

^h HK-MOCA replaced AMIC in a later stage.

ⁱ Better result of two series for left or right hand, or best result of both hands.

1
2
3
4
5 Figure 1 Flowchart of recruitment
6
7
8
9
10
11
12

13
14 Figure 2a Unweighted prevalence of co-morbidities (by 15 disease categories) among the 1077
15 elderly with multimorbidity

16
17 (Figures are unweighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK:
18 Musculoskeletal Disorders; ENT: eye, nose and throat)
19
20

21
22 Figure 2b Weighted prevalence of co-morbidities (by 15 disease categories) among the 1077
23 elderly with multimorbidity

24
25 (Figures are weighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK:
26 Musculoskeletal Disorders; ENT: eye, nose and throat)
27
28
29
30
31
32
33

34
35 Figure 3a Unweighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43
36 specific chronic conditions) among the 1077 elderly with multimorbidity

37
38 (Figures are unweighted prevalence (%))
39
40

41
42 Figure 3b Weighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43
43 specific chronic conditions) among the 1077 elderly with multimorbidity

44
45 (Figures are weighted prevalence (%))
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flowchart of recruitment




Figure 2a Unweighted prevalence of co-morbidities (by 15 disease categories) among the 1077 elderly with multimorbidity

(Figures are unweighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK: Musculoskeletal Disorders; ENT: eye, nose and throat)




Figure 2b Weighted prevalence of co-morbidities (by 15 disease categories) among the 1077 elderly with multimorbidity

(Figures are weighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK: Musculoskeletal Disorders; ENT: eye, nose and throat)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 3a Unweighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43 specific chronic conditions) among the 1077 elderly with multimorbidity (Figures are unweighted prevalence (%))




Figure 3b Weighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43 specific chronic conditions) among the 1077 elderly with multimorbidity (Figures are weighted prevalence (%))

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p2	Cross-sectional study, with results weighted according to the census.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	p2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	p5-6	
Objectives	3	State specific objectives, including any prespecified hypotheses	p6	
Methods				
Study design	4	Present key elements of study design early in the paper	p6	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p6-9	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	p6-7	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p7-9, p19-21 (Table 1)	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p7-9, p19-21 (Table 1)	
Bias	9	Describe any efforts to address potential sources of bias	p9	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Study size	10	Explain how the study size was arrived at	p7
------------	----	---	----

Continued on next page

For peer review only

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	p9
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	p9
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	p10-11
		(b) Indicate number of participants with missing data for each variable of interest	p10-11, p23-27 (Table 2), Figure 2, Figure 3
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	p10-11 and p23-27 (Table 2), Figure 2, Figure 3
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were	NA

1
2 included

3 (b) Report category boundaries when continuous variables were categorized

p23-27

(Table 2)

4
5
6 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time
7 period

NA

8
9 Continued on next page

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA	
Discussion				
Key results	18	Summarise key results with reference to study objectives	p11	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p13-14	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p12-13	
Generalisability	21	Discuss the generalisability (external validity) of the study results	p14	
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p1	Funding The work was supported by The Hong Kong Jockey Club Charities Trust.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Cohort profile: The prospective study on Chinese elderly with multimorbidity in primary care in Hong Kong

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027279.R2
Article Type:	Cohort profile
Date Submitted by the Author:	08-Jan-2020
Complete List of Authors:	ZHANG, Dexing; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Sit, Regina Wing Shan; The Chinese University of Hong Kong, JC School of Public Health and Primary Care Wong, Carmen; The Chinese University of Hong Kong , Jockey Club School of Public Health and Primary Care Zou, Dan; The Chinese University of Hong Kong, JC School of Public Health and Primary Care Mercer, Stewart; University of Glasgow, Institute of Health and Wellbeing Johnston, Marjorie; University of Aberdeen, Wong, Samuel; Chinese University of Hong Kong, School of Public Health and Primary Care
Primary Subject Heading:	Patient-centred medicine
Secondary Subject Heading:	Epidemiology, Evidence based practice, General practice / Family practice, Geriatric medicine, Health services research
Keywords:	Chronic conditions, Comorbidities, Older Adults, General practice, Physical, Psychological and Social Factors, PRIMARY CARE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Cohort profile: The prospective study on Chinese elderly with multimorbidity in primary**
4 **2 care in Hong Kong**

5
6
7 3 Dexing Zhang,¹ Regina Wing Shan Sit,¹ Carmen Wong,¹ Dan Zou,¹ Stewart W. Mercer,² Marjorie
8 4 Johnston,³ Samuel Yeung Shan Wong^{1*}
9

- 10
11
12 6 1. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR
13 7 2. The Usher Institute of Population Health Sciences and Informatics, Medical School, University of Edinburgh,
14 8 The United Kingdom
15 9 3. The Institute of Applied Health Sciences, University of Aberdeen, The United Kingdom
16
17
18 10

19 **11 * Corresponding Author:**

20
21 12 Name: Samuel Yeung Shan WONG
22 13 Email: yeungshanwong@cuhk.edu.hk
23 14 Tel: (852) 2252 8774
24 15 Fax: (852) 2606 3500
25 16 Address: 4/F, JC School of Public Health and Primary Care, Prince of Wales Hospital, Shatin, N.T., Hong
26 17 Kong
27
28
29
30
31

32 **19 Funding**

33 20 The staff working on this cohort received funding from the Hong Kong Jockey Club Charities Trust.

34 **21 Acknowledgements**

35 22 We would like to thank the General Out-patient Clinics (Lek Yuen, Ma On Shan, Shatin (Tai Wai), Yuen Chau Kok)
36 23 and Shatin Rhenish Neighbourhood Elderly Centre for the support and help in recruitment. We also greatly thank all
37 24 the patients who joined in the cohort.

38 25 **Patient consent** Obtained

39 26 **Ethics approval** Compliance with Ethical Standards. Ethics approval was obtained from the Joint Chinese University
40 27 of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee (The Joint CUHK-NTEC CREC).

41 28 **Conflict of Interest** None declared.

42 29 **Contributors** SYSW conceived and supervised the study and revised the manuscript. DXZ contributed to study design,
43 30 analysed the data, prepared the draft and revised the manuscript. SRWS and CW contributed to the study design and
44 31 implementation, and manuscript revisions. DZ contributed in data collection and manuscript revisions. SWM and MJ
45 32 contributed in manuscript revisions.
46
47
48
49
50
51

52 34 **Word count:** 3374 words (excluding abstract, references, tables and figures)
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Purpose**

3 This is an ongoing prospective cohort aiming to examine the biopsychosocial health profiles and predictors
4 of health outcomes of older patients with multimorbidity in primary care in Hong Kong.

5 **Participants**

6 From April 2016 to October 2017, 1077 patients aged 60+ years with at least two chronic diseases were
7 recruited in 4 public primary care clinics in the New Territories East Region of Hong Kong.

8 **Findings to date**

9 After weighting, the patients had 4.1 (1.8) chronic conditions and 2.5 (1.9) medications on average; 37%
10 forgot taking medication sometimes; 71% rated their health as fair or poor; 17% were frail; 73% reported
11 one (21%) or two or more (52%) body pain areas; 62% were overweight/obese; 23% reported chewing
12 difficulty, 18% reported incontinence; 36% had current Stage 1/2 hypertension; 38% had handgrip strength
13 below the cut-off; 18% screened positive in sarcopenia; 12% had mild cognitive impairment; 17% had mild
14 to severe depression; 17% had mild to severe anxiety; 50% had sub-threshold to severe insomnia; 28%
15 indicated being lonely; 12% needed help in at least one out of the five daily functions; and the EQ-5D-5L
16 index score was 0.81 (0.20) and its visual analogue scale (VAS) score was 67.6 (14.6). In the past 12 months,
17 17% were hospitalized, 92% attended general out-patient clinics (GOPC), 70% attended specialist out-
18 patient clinics (SOPC), and 10% used elderly daycare center services, the median out-of-pocket health cost
19 was 1000 HK\$ (US\$150). Female and male patients showed significant differences in many
20 biopsychosocial health aspects.

21 **Future plans**

22 With assessments and clinical data, the cohort can be used for understanding longitudinal trajectories of
23 biopsychosocial health profiles of Chinese older patients with multimorbidity in primary care. We are also
24 initially planning cohort studies on factors associated with various health outcomes, as well as quality of
25 life and healthcare use.

26 **Cohort Registration:** ChiCTR-OIC-16008477

27 **Key Words:**

28 Multimorbidity; Prospective Cohort; Older Adults; Primary Care; Physical, Psychological and Social Risk
29 Factors

Strengths and limitations of this study

- This prospective cohort comprehensively examines biopsychosocial health problems encountered by Chinese older patients with multimorbidity in a primary care program in Hong Kong. As far as we are aware of, very few prospective cohorts specifically cover this population in primary care, and no such prospective cohort exists among Chinese.
- The data could be linked with electronic health records to allow follow up and examination of long-term outcomes associated with multimorbidity, and predictors of those outcomes.
- The limitation was that older adult patients who were male, disabled, very ill, institutionalized, or house-bounded were less likely to have participated in this study; a few assessments were only conducted within subgroups or added at a later stage; the sample size may limit examinations of potential interactions and factors associated with multimorbidity in some subgroups.
- The baseline health results had been weighted according to the census data. The weighted rates might be an underestimation of the rates among the primary care patients and be close to the rates of the general population.

1 INTRODUCTION

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Multimorbidity, defined as patients living with two or more chronic health conditions, is common in primary care. The prevalence is increasing over the last decades as a result of an aging population and changes in lifestyles e.g. more sedentary lifestyle which have increased the risk of obesity, resulting in a higher risk of developing chronic conditions.^{1 2} A recent systematic review suggests that the prevalence of multimorbidity is high among the elderly ranging from 12.9% to 95.1% in different studies.³ Multimorbidity is associated with increased disability and depression, reduced quality of life, and higher rates of adverse drug consequences.⁴ Multimorbidity also leads to increased primary and secondary health service utilization, especially unplanned health care, as well as reduced life-expectancy.⁵ The direct and indirect economic burden associated with multimorbidity is huge.⁶ The annual healthcare costs were €4,096.86 among patients with 5 or more chronic conditions, which was almost 5 times more than those who were healthy in a study in the West of Ireland.⁷ It has been estimated that by 2030, 66% of the global disease burden will be due to chronic diseases, with most of the burden occurring in the most populous area – Asia.^{8 9} The economic burden highlights an urgent need for holistic understanding of patients with multimorbidity when searching for cost-effective ways to manage these patients, given that treatment of diseases in isolation can be inefficient, leading to duplication of care and poorer health outcomes.¹⁰

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Studies on multimorbidity have increased in recent years,¹¹⁻²⁰ and a clinical guideline on clinical assessment and management of multimorbidity was developed by the National Institute for Health and Care Excellence (NICE) in the UK in 2016.²¹ However, studies are still needed for the epidemiology and profiles of patients with multimorbidity and their longitudinal outcomes to inform policy making in different populations including Chinese primary care patients.^{3 22} Most studies on primary care patients with multimorbidity are conducted in western countries such as UK, USA, Australia, Spain and Belgium,^{14 15 23-29} and limited research has been conducted on psychological and social problems accompanying with multimorbidity.^{3 21 22 30 31} Several longitudinal studies of multimorbidity have been conducted in Asian populations,³²⁻³⁴ but none of these are of primary care patients. Important knowledge gaps still exist regarding the biopsychosocial health profiles of patients with multimorbidity in primary care among Asian

1 Chinese.³⁵ Therefore, more studies among Chinese patients with multimorbidity in primary care
2 are needed to advance our understanding for services.^{14 36-40}

3 This study focuses on the elderly in Hong Kong, where the population is ageing rapidly.
4 Hong Kong has a population of 7.34 million according to the 2016 census data, with 23.7% aged
5 60 years or above. The rate was higher than the proportions in 2006 (16.5%) and 2011 (19.5%).⁴¹
6 In Hong Kong, although there is a large private primary care sector, around 85% of people with
7 chronic conditions are managed in the public primary care setting. Given that the Hong Kong
8 population has the longest life expectancy in the world: (81.7 for men and 87.7 for women in
9 2017),⁴² the ageing population and multimorbidity have brought much burden and challenge to the
10 local healthcare system. To inform healthcare providers and policymakers in allocating suitable
11 health services for people with multimorbidity in primary care, the present study aimed to study
12 the longitudinal biopsychosocial health profiles and also predictors of health outcomes of Chinese
13 patients with multimorbidity who present to public primary care in Hong Kong.

15 **COHORT DESCRIPTION**

16 **Study setting and participants**

17 This study contains primary care patients from four general out-patient clinics (GOPCs) out of the
18 ten general out-patient clinics (GOPCs) in the New Territory East Cluster (NTEC), Hong Kong,
19 as permission to recruit from these four clinics was given by the local regulator (the Hospital
20 Authority) during the study period. Each GOPC receives about 450 patients each day. The working
21 hours are generally from 9:00 am to 5:00 pm from Monday to Friday with some additional night
22 and weekend sessions. In the most recent Hospital Authority Annual Report 2016-2017, the ten
23 GOPCs in NTEC provided 972,454 consultations in total in the year of 2015/2016, which consisted
24 of one third of total GOPC consultations in Hong Kong public health system.⁴³

25 The inclusion criteria of participants were: 1) aged 60 years or above; 2) with two or more
26 chronic diseases confirmed by the medical information in the public Clinical Management System
27 (CMS) and patients' self-report; and 3) could speak and understand Chinese. No specific exclusion
28 criteria were adopted. However, as participants needed to respond to questionnaire surveys and
29 health checks, they should be able to access the clinic, sign informed consent by themselves, and
30 understand and answer the research questions.

1 Patients were first consecutively screened for eligibility by trained research assistants in
2 the waiting areas of the GOPCs. For those who were eligible, they were asked to provide a contact
3 phone number and then were scheduled to visit the study nurse for further assessments. All patients
4 provided informed consent before participation in the study. From April 2016 to October 2017,
5 1077 eligible patients were recruited and completed the baseline assessments. The baseline
6 assessments were conducted through face-to-face interviews by nurses or a social worker at a
7 university affiliated primary care clinic. The flowchart of recruitment is shown in **Figure 1**. The
8 sample size allows a margin of error at 3% with a confidence interval of 95%. It is also 100%
9 powered to detect a mean difference of 0.5 (assuming standard deviation is 1.0) and 90% powered
10 to detect a difference of 8% of different rates, with a follow-up rate of 50% ($\alpha=0.05$).^{44 45}

11 12 **Measures**

13 The assessments covered a range of measures that are postulated to be potential physical,
14 psychological and social factors associated with multimorbidity. Each complete assessment lasted
15 for about 45 to 60 minutes. All the measures were validated and have been widely used or have
16 been used in our previous studies. Information was collected through face-to-face interviews by
17 trained nurses, social workers and research assistants, and additional information of the disease
18 entities, medication use and health service utilization was confirmed through the review of
19 electronic medical records by nurses. The electronic medical records include patient information
20 and diagnosis, health examinations, medication prescription, and health visits to the public health
21 system. The records cover all patients who seek medical services in public health system. It is a
22 medical record system of routine clinical practices with quality ensured by all healthcare
23 professionals including trained doctors, nurses and allied health professionals under Hospital
24 Authority in Hong Kong.

25 The measures in the questionnaires included: 1) the number and type of chronic diseases
26 in fifteen categories (a total of 43 chronic conditionals) adapted slightly by a group of family
27 physicians and researchers based on chronic conditions employed in previous studies^{46 47} and the
28 International Statistical Classification of Diseases 11 (ICD-11). Details can be seen in Table 1; 2)
29 depression (screened by the 2-item Patient Health Questionnaire (PHQ-2)).⁴⁸ Those with a score
30 of 3 or more (which suggests depression) were further measured by the 9-item Patient Health
31 Questionnaire (PHQ-9);⁴⁹ 3) anxiety (screened by the 2-item Generalised Anxiety Disorder (GAD-

1 2)). Those with a score of 3 or more (which suggests anxiety) were further measured by the 7-item
2 Generalised Anxiety Disorder (GAD-7);⁵⁰ 4) loneliness (measured by the 6-item De Jong Gierveld
3 Loneliness Scale),⁵¹ as well as one loneliness question; 5) insomnia (measured by the 7-item
4 Insomnia Severity Index (ISI))⁵² among those who answered yes to a screening question); 6) pain
5 (measured by the Brief Pain Inventory among those who were screened positive in pain); 7)
6 physical activity (measured by Physical Activity Scale for the Elderly (PASE))⁵³ among those who
7 were screened positive in pain); 8) frailty (measured by the Edmonton Frail Scale⁵⁴ which was
8 translated and back-translated by experienced bilingual translators); 9) meaning of existence
9 (measured by one question extracted from the validated Chinese Purpose in Life test (CPIL) which
10 was used in a previous study);⁵⁵ 10) sarcopenia (measured by the 5-item Sarcopenia Assessment
11 (SARC-F));^{56,57} 11) cognition (measured by the Hong Kong Montreal Cognitive Assessment (HK-
12 MoCA) with a score of 22 or above being with normal cognition);⁵⁸ 12) alcohol use (screened by
13 one question and then measured by the 3-item Alcohol Use Disorders Identification Test-
14 consumption (AUDIT-C) for those who screened positive); 13) smoking (non-smoker, current
15 smoker, ex-smoker); 14) medication use (number and duration (0-1 year/2-5 years/>5 years) of
16 antihypertensive, cardiovascular and hypolipidemic drugs, antidiabetics, antipsychotics and
17 analgesics was checked in electronic medical system, and compliance of medication use was
18 measured by “At times, do you forget to take your prescription medications?” (no/yes)); 15) self-
19 rated health; 16) community network; 17) use of social media (measured by a screening question,
20 and for those who answered yes to any of the social media, they were further assessed on the
21 importance and comfort of using the internet); 17) oral health; 18) incontinence; 19) caregiving to
22 somebody; 20) quality of life (measured by the EuroQol EQ-5D-5L (EQ5D));⁵⁹ 21) daily function
23 (ability to use the telephone, mode of transportation, shopping, food preparation, ability to handle
24 finances were measured); 22) health service utilization (visits to primary care doctors, specialist
25 outpatient clinics, admission to hospital, use of services in elderly daycare centers and out-of-
26 pocket healthcare costs which were not covered by public health system or insurance both in
27 private and public in the past year). In addition, physical examinations included blood pressure,
28 Body Mass Index (BMI), waist circumference and handgrip strength (kg). For blood pressure, two
29 assessments were taken by the nurses. Patients sat for at least 5 minutes before the first assessment,
30 and they were assessed again 15 minutes later. Handgrip strength was also assessed twice for each
31 hand. Social economic status such as age, gender, marriage, living status, employment, receiving

1 of social welfare scheme was also included. Due to the data collection plan amendments, a few
2 measures were only collected in a sub-group of the patients at a later stage. Summaries of the
3 baseline measures are described in **Table 1**.

4 The questionnaire was set up in password protected EpiData files in a password protected
5 computer with quality control. For example, for scale questions with answers on a Likert scale of
6 1 to 5, a range of 1-5 and one digit was set up so no other results were allowed during data entry.
7 Additionally, for most data variables, a “must enter” was set up, so that the question could not be
8 missed unless answered or an individual purposely moves to the next question. Checking for
9 missing data was done regularly by experienced researchers and missing data was further collected
10 by nurses through face-to-face interviews, telephone or by checking the electronic medical record
11 system.

13 **Patient and Public Involvement**

14 The research questions and outcome measures were developed based on some most common
15 problems that are widely recognized among elder patients. Patients or the public did not involve
16 in the design of the study, recruitment or conduction of the study. The results of the study would
17 be disseminated to patients once he or she requests so and aggregated data would be reported in
18 project reports and research publications and conferences.

20 **Findings to date**

21 Baseline characteristics of the patients in the study are shown in **Table 2**. The weighted data are
22 shown in the bracket beside the unweighted data. The mean age of the study patients was 70
23 (SD=6.8) (70.5, SD=7.9) years, 70% (52.8%) were female, 67% (68%) were married, 14% (15%)
24 lived alone, 92% (87%) were retired or housewives, 49% (52%) had 6 years of education or above,
25 10% (10%) were on the Comprehensive Social Security Assistance (CSSA) scheme which is open
26 for those with a low income, about half used social media in the last 2 weeks, about 18% (15%)
27 provided care to another (such as their spouse or children/grandchildren), 12% (17%) had drunk
28 alcohol in the past year and 3% (4%) were current smokers. More female patients lived alone, were
29 retired/housewives, had lower education, and had more social security support than male patients
30 (p values < 0.05).

1
2
3 1 After weighting, overall, the mean number of chronic diseases was 4.1 (SD=1.8) and about
4 2 one in five patients had 6 or more chronic diseases. The top three chronic conditions were
5 3 hypertension (75%), dyslipidemia (46%), and skeletal and connective tissue inflammation (e.g.
6 4 arthritis) (36%). The unweighted and weighted prevalence of co-morbidities of the 15 disease
7 5 categories among the patients is shown in **Figure 2** and **Figure 3**, respectively. The unweighted
8 6 and weighted co-morbidities of top 10 prevalent conditions out of the 43 conditions are shown in
9 7 **Figure 4** and **Figure 5**, respectively, with the combination of hypertension and dyslipidemia being
10 8 the most common (39%), followed by hypertension and diabetes mellitus (27%), hypertension and
11 9 skeletal and connective tissue inflammation (e.g. arthritis) (26%), dyslipidemia and diabetes
12 10 mellitus (21%), hypertension and chronic pain (20%). Information of the rest co-morbidities is
13 11 shown in the figures. Female patients had fewer number of chronic conditions, fewer number of
14 12 medications in use but poorer self-rated health than male patients (p values < 0.05). On average,
15 13 patients took 2.5 (SD=1.9) medications, with 30% taking 5 or more medications regularly, 36%
16 14 reported forgot taking medication sometimes.

17 15 After weighting, the mean BMI was 24.3 (SD=3.4) with 61% being overweight or obese.
18 16 Based on the Edmonton Frail Scale, 17% were frail. Eight percent had sarcopenia, 23% reported
19 17 chewing difficulty, 18% reported incontinence, 36% had stage one or two hypertension currently
20 18 according to the physical examination, 38% had their handgrip strength (based on the best outcome
21 19 of two trials of both hands) below the cut-off point, 12% needed help or were dependent in at least
22 20 one out of the 5 daily functions (using telephone, transportation, shopping, preparing meals, or
23 21 financial management). Overall, 30%, 59% and 11% of patients rated their health being
24 22 'excellent/very good/good', 'fair', or 'poor' respectively. Seventy-three percent reported the
25 23 presence of one (21%) or two or more (52%) body pain areas, 17% scored the HK-MoCA <22
26 24 suggesting at least mild cognitive impairment; 18% had PHQ-2 ≥ 3 , while 17% had PHQ-9 ≥ 5
27 25 suggesting mild depression or more severe; 15% had GAD-2 ≥ 3 , while 16% had GAD-7 ≥ 5
28 26 suggesting mild anxiety or more severe; 50% had insomnia at subthreshold level or above, the
29 27 mean score of the meaning of existence was 4.9 (SD=1.2) out of 7, 28% reported feeling lonely.
30 28 More finding details can be seen in **Table 2**. More female patients had incontinence, pain,
31 29 sarcopenia and cognitive impairment than male patients. Female patients were more likely to be
32 30 screened positive in depression and anxiety, reported severer level of insomnia and reported lower
33 31 perceived existence of meaning than male patients. Female patients were more likely to be frail.

1
2
3 1 More male patients used social media (p values < 0.05). The loneliness level and perceived social
4 2 support were not significantly different between female and male patients.

5
6 3 In addition, after weighting, the EQ-5D-5L index score was 0.81 (0.20) and its visual
7 4 analogue scale (VAS) score was 67.6 (14.6) out of 100. Female patients showed poorer quality of
8 5 life. In the last year, 17% were admitted to hospital, 92% attended GOPC, 70% attended SOPC,
9 6 10% used elderly day care center services and the median out-of-pocket health cost was 1000 HK\$
10 7 (US\$150) for any health expenditures not covered by the public health system or insurance. Male
11 8 patients reported more GOPC visits than female patients in the past year ($p=0.007$).
12 9
13 10

11 **Future plans**

12 11 The patients will be followed-up regularly (interval of ~2 years) to monitor changes in health status
13 12 and outcomes through data collected from questionnaires, physical assessments and clinical
14 13 records. Key biopsychosocial assessments such as depression, anxiety, loneliness, pain, frailty, as
15 14 well as quality of life would be included in the follow-up assessments, but each follow-up might
16 15 be added with some additional assessments with specific research interests. The first follow-up
17 16 (i.e., wave 2 assessment) had started in early 2018. Additional information on mobility by the 30
18 17 second chair-stand test, visual acuity by Amsler Grid test and hearing by Weber's test and Rinne
19 18 Test were added. Information on electronic medical records will also be updated to provide
20 19 information on health service utilization, changes in medication use, and new onset of diseases
21 20 and death.

22 21 The longitudinal trajectories of biopsychosocial health profiles of these primary care
23 22 patients will be described. For example, changes and occurrence of different physical, mental and
24 23 social problems among all the study participants as well as some subgroups (e.g. different age,
25 24 gender, co-morbidities). We are also initially planning cohort studies on factors associated with
26 25 various health outcomes as well as quality of life and healthcare use. In addition, more explorations
27 26 will be made to answer many other research questions based on hypotheses.
28 27
29 28

29 **Strengths and limitations**

30 29 This study has several strengths. First, this is one of the few etiological studies on older
31 30 adults being conducted in Asian primary care settings to examine physical, psychological and
32 31 social problems accompanying with multimorbidity. Second, it prospectively covers a range of
33 32
34 33
35 34
36 35
37 36
38 37
39 38
40 39
41 40
42 41
43 42
44 43
45 44
46 45
47 46
48 47
49 48
50 49
51 50
52 51
53 52
54 53
55 54
56 55
57 56
58 57
59 58
60 59

1
2
3 1 biopsychosocial factors which are not included in other previous large-scale studies since plenty
4 2 of them are derived from extracted medical or insurance records. Our findings suggest that people
5 3 with multimorbidity have significant complex healthcare needs in physical, mental and social
6 4 aspects such as obesity, multiple body pain, polypharmacy, depression, anxiety, insomnia and
7 5 loneliness. The results suggested that a holistic approach that addresses general physical and
8 6 functional domain of health, at the same time assessing and managing psychological and social
9 7 problems is therefore needed in the care of older adults with multimorbidity. Services which are
10 8 designed to cater for the complex needs of elder patients with multimorbidity from biopsychosocial
11 9 perspectives are urgently needed. These service models should also be adapted and tested in local
12 10 circumstances to maximize its efficacy. Furthermore, given the significant differences found
13 11 between male and female patients in biopsychosocial aspects, future interventions may also need
14 12 to take gender differences into account. Third, the results were weighted according to the census
15 13 data to make the sample more representative of the general population. In general, the weighted
16 14 results were similar to the unweighted results, and in consistency with results reported in the
17 15 western populations. Fourth, because it contains linked electronic medical records, it will allow us
18 16 to follow them up for public medical service use and mortality.

19 17 There are also several limitations. First, self-selection bias might still exist which was
20 18 consistent with other similar studies,⁶⁰ although we used weighting for adjustment, as not all
21 19 variables were available for weighting such as education. Since only ambulatory adults who agreed
22 20 to join were recruited and these usually are more likely to be female and those with higher
23 21 educational level and higher self-motivation, and those who were house-bound or institutionalized
24 22 are less likely to have been included, we might have resulted in a relatively healthier and higher-
25 23 functioning patients in primary care, and the real health status might be worse than what are
26 24 reported in our study. Future studies may need to take measures to increase participation from
27 25 male and vulnerable patients. Second, the sample size may limit examinations of potential
28 26 interactions and factors associated with multimorbidity in some subgroups such as older men and
29 27 people with lower educational levels, or uncommon health problems among these patients. Third,
30 28 we used a two-step assessment for some health indicators. While false negative reported rates of
31 29 pain, insomnia and alcohol use were unlikely, there might be false negative rates for depression
32 30 and anxiety as the specificity and sensitivity of PHQ-2 and GAD-2 were not 100% (although
33 31 results from meta-analytic reviews suggest they are reasonable to use in initial screening).^{61 62} In

1
2
3 1 addition, as PHQ-2 and GAD-2 are often used for screening with results in dichotomies
4 (negative/positive), this might limit application of some statistical analysis such as using growth
5 2 models in future longitudinal data. Fourth, for a few assessments, we only conducted them among
6 3 a subgroup of participants, e.g. PASE for physical activity among those patients with pain.
7 4 Furthermore, some additional assessments such as meaning, sarcopenia, oral health were added at
8 5 a later stage. So only subgroup data could be reported in this paper or analyzed in the future when
9 6 using these data.
10 7
11 8

9 **Data Sharing**

10 Data will be available upon reasonable request. The authors warmly welcome collaborations for
11 future research based on this study. For those who would like to request for the data or propose
12 new assessments into the follow-up assessments, they can email to:
13 [yeungshanwong@cuhk.edu.hk]. For more information please see the website:
14 <http://cpep.sphpc.cuhk.edu.hk/chi/>.
15
16
17

18 **Reference**

- 19 1. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the
20 last 20 years. *The European journal of general practice* 2008;14 Suppl 1:28-32. doi:
21 10.1080/13814780802436093 [published Online First: 2008/10/31]
- 22 2. Pefoyo AJ, Bronskill SE, Gruneir A, et al. The increasing burden and complexity of
23 multimorbidity. *BMC public health* 2015;15:415. doi: 10.1186/s12889-015-1733-2
24 [published Online First: 2015/04/24]
- 25 3. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of
26 multimorbidity in primary care: A systematic review of observational studies: PLoS
27 ONE. 9 (7) , 2014. Article Number: e102149. Date of Publication: 21 Jul 2014. 2014.
- 28 4. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of
29 the literature. *Ageing Res Rev* 2011;10(4):430-9. doi: 10.1016/j.arr.2011.03.003
30 [published Online First: 2011/03/16]
- 31 5. Salisbury C. Multimorbidity: Time for action rather than words: *British Journal of General*
32 *Practice*. 63 (607) (pp 64-65), 2013. Date of Publication: February 2013. 2013.
- 33 6. Picco L, Achilla E, Abdin E, et al. Economic burden of multimorbidity among older adults:
34 impact on healthcare and societal costs. *Bmc Health Serv Res* 2016;16 doi: Artn
35 1731186/S12913-016-1421-7

- 1 7. Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and
2 its effect on health care utilization and cost. *Family practice* 2011;28(5):516-23. doi:
3 10.1093/fampra/cmr013
- 4 8. World Health Organization. The global burden of disease: 2004 update. 2008, 2011.
- 5 9. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years
6 (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195
7 countries and territories, 1990-2016: a systematic analysis for the Global Burden of
8 Disease Study 2016. *Lancet* 2017;390(10100):1260-344. doi: 10.1016/S0140-
9 6736(17)32130-X
- 10 10. Salisbury C. Multimorbidity: Redesigning health care for people who use it: The Lancet. 379
11 (9836) (pp 7-9), 2012. Date of Publication: July 2012. 2012.
- 12 11. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort Profile: The
13 Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. *Int*
14 *J Epidemiol* 2018;47(2):382-84f. doi: 10.1093/ije/dyx259 [published Online First:
15 2018/01/19]
- 16 12. Hanlon P, Nicholl BI, Jani BD, et al. Frailty and pre-frailty in middle-aged and older adults
17 and its association with multimorbidity and mortality: a prospective analysis of 493 737
18 UK Biobank participants, 2018.
- 19 13. Wei MY, Kabeto MU, Galecki AT, et al. Physical Functioning Decline and Mortality in
20 Older Adults with Multimorbidity: Joint Modeling of Longitudinal and Survival Data.
21 *Journals of Gerontology Series A Biological Sciences & Medical Sciences* 2018;26:26.
22 doi: <https://dx.doi.org/10.1093/gerona/gly038>
- 23 14. Ibarra-Castillo C, Guisado-Clavero M, Violan-Fors C, et al. Survival in relation to
24 multimorbidity patterns in older adults in primary care in Barcelona, Spain (2010-2014):
25 a longitudinal study based on electronic health records. *Journal of Epidemiology &*
26 *Community Health* 2018;72(3):185-92. doi: <https://dx.doi.org/10.1136/jech-2017-209984>
- 27 15. Guisado-Clavero M, Roso-Llorach A, López-Jimenez T, et al. Multimorbidity patterns in the
28 elderly: a prospective cohort study with cluster analysis. *Bmc Geriatr* 2018;18(1):16.
- 29 16. Katikireddi SV, Skivington K, Leyland AH, et al. The contribution of risk factors to
30 socioeconomic inequalities in multimorbidity across the lifecourse: a longitudinal
31 analysis of the Twenty-07 cohort. *BMC medicine* 2017;15(1):152.
- 32 17. Jensen NL, Pedersen HS, Vestergaard M, et al. The impact of socioeconomic status and
33 multimorbidity on mortality: a population-based cohort study. *Clinical Epidemiology*
34 2017;9:279-89. doi: 10.2147/Clep.S129415
- 35 18. Walker V, Perret-Guillaume C, Kesse-Guyot E, et al. Effect of Multimorbidity on Health-
36 Related Quality of Life in Adults Aged 55 Years or Older: Results from the SU.VI.MAX
37 2 Cohort. *PloS one* 2016;11(12) doi: ARTN e01692821371/journal.pone.0169282
- 38 19. Prior A, Fenger-Gron M, Larsen KK, et al. The Association Between Perceived Stress and
39 Mortality Among People With Multimorbidity: A Prospective Population-Based Cohort
40 Study. *Am J Epidemiol* 2016;184(3):199-210. doi: 10.1093/aje/kwv324
- 41 20. Vos R, van den Akker M, Boesten J, et al. Trajectories of multimorbidity: exploring patterns
42 of multimorbidity in patients with more than ten chronic health problems in life course.
43 *Bmc Fam Pract* 2015;16(1):2.
- 44 21. Farmer C, Fenu E, O'flynn N, et al. Clinical assessment and management of multimorbidity:
45 summary of NICE guidance. *BMJ: British Medical Journal (Online)* 2016;354

- 1 22. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, et al. Cohort Profile: The
2 Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study.
3 *International journal of epidemiology* 2018;47(2):382-84f.
- 4 23. Gunn JM, Ayton DR, Densley K, et al. The association between chronic illness,
5 multimorbidity and depressive symptoms in an Australian primary care cohort. *Social*
6 *psychiatry and psychiatric epidemiology* 2012;47(2):175-84. doi: 10.1007/s00127-010-
7 0330-z
- 8 24. Mavaddat N, Valderas JM, van der Linde R, et al. Association of self-rated health with
9 multimorbidity, chronic disease and psychosocial factors in a large middle-aged and older
10 cohort from general practice: a cross-sectional study, 2014.
- 11 25. Bock J-O, Luppá M, Brettschneider C, et al. Impact of depression on health care utilization
12 and costs among multimorbid patients—results from the multicare cohort study. *PloS one*
13 2014;9(3):e91973.
- 14 26. Calderon-Larranaga A, Hernandez-Olivan P, Gonzalez-Rubio F, et al. Multimorbidity and
15 weight loss in obese primary care patients: Longitudinal study based on electronic
16 healthcare records, 2015.
- 17 27. France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: A systematic review of
18 prospective cohort studies, 2012.
- 19 28. Boeckxstaens P, Vaes B, Legrand D, et al. The relationship of multimorbidity with disability
20 and frailty in the oldest patients: A cross-sectional analysis of three measures of
21 multimorbidity in the BELFRAIL cohort, 2015.
- 22 29. Brettschneider C, Leicht H, Bickel H, et al. Relative impact of multimorbid chronic
23 conditions on health-related quality of life—results from the MultiCare Cohort Study. *PloS*
24 *one* 2013;8(6):e66742.
- 25 30. Mercer SW, Gunn J, Wyke S. Improving the health of people with multimorbidity: the need
26 for prospective cohort studies: SAGE Publications Sage UK: London, England, 2011.
- 27 31. France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: a systematic review of
28 prospective cohort studies. *Br J Gen Pract* 2012;62(597):e297-e307.
- 29 32. Kuo RN, Lai MS. The influence of socio-economic status and multimorbidity patterns on
30 healthcare costs: a six-year follow-up under a universal healthcare system. *International*
31 *journal for equity in health* 2013;12:69. doi: 10.1186/1475-9276-12-69
- 32 33. Gu J, Chao J, Chen W, et al. Multimorbidity and health-related quality of life among the
33 community-dwelling elderly: A longitudinal study, 2018.
- 34 34. Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11
35 Asian regions: A prospective cohort study using the ASIAN-HF registry, 2018.
- 36 35. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges
37 of applying UK clinical guidelines to people with multimorbidity. *Age and ageing*
38 2012;42(1):62-69.
- 39 36. Muth C, Beyer M, Fortin M, et al. Multimorbidity's research challenges and priorities from a
40 clinical perspective: The case of 'Mr Curran': *European Journal of General Practice*. 20
41 (2) (pp 139-147), 2014. Date of Publication: June 2014. 2014.
- 42 37. Fortin M, Lapointe L, Hudon C, et al. Multimorbidity is common to family practice: is it
43 commonly researched?: *Canadian family physician Medecin de famille canadien*. 51 (pp
44 244-245), 2005. Date of Publication: Feb 2005. 2005.

- 1
2
3 1 38. Kadam U. Redesigning the general practice consultation to improve care for patients with
4 2 multimorbidity: BMJ (Online). 345 (7878) , 2012. Article Number: e6202. Date of
5 3 Publication: 13 Oct 2012. 2012.
6 4
7 4 39. Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic
8 5 review of interventions in primary care and community settings. *Bmj* 2012;345:e5205.
9 6 40. Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary
10 7 care. *Bmj* 2015;350(176):10.1136.
11 8 41. The Government of Hong Kong Special Administrative Region (HKSAR). 2016 Population
12 9 By-census. <http://wwwbycensus2016govhk/en/bc-mthtml> 2018; Accessed on July 31,
13 10 2018
14 11 42. Centre for Health Protection, Department of Health, The Government of the Hong Kong
15 12 Special Administrative Region, . Life Expectancy at Birth (Male and Female), 1971 -
16 13 2017 <https://wwwchpgovhk/en/statistics/data/10/27/111html> 2018; Accessed on July 23
17 14 2018
18 15 43. Hospital Authority, HKSAR. Hospital Authority Annual Report 2016-2017.
19 16 <http://wwwhaorghk/ho/corppcomm/AR201617/ebook/en/mobile/indexhtml#p=1> Accessed
20 17 on July 23 2018.
21 18 44. Rosner B. Fundamentals of Biostatistics. 6th ed. Pacific Grove, CA: Brooks/Cole; 2006.
22 19 2006
23 20 45. Levine M, Ensom MHJPTJoHP, Therapy D. Post hoc power analysis: an idea whose time
24 21 has passed? 2001;21(4):405-09.
25 22 46. Wang HH, Wang JJ, Wong SY, et al. Epidemiology of multimorbidity in China and
26 23 implications for the healthcare system: cross-sectional survey among 162,464 community
27 24 household residents in southern China. *BMC Med* 2014;12:188. doi: 10.1186/s12916-
28 25 014-0188-0 [published Online First: 2014/10/24]
29 26 47. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications
30 27 for health care, research, and medical education: a cross-sectional study. *Lancet*
31 28 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2 [published Online First:
32 29 2012/05/15]
33 30 48. Yu XN, Stewart SM, Wong PTK, et al. Screening for depression with the Patient Health
34 31 Questionnaire-2 (PHQ-2) among the general population in Hong Kong. *Journal of*
35 32 *Affective Disorders* 2011;134(1-3):444-47. doi: 10.1016/j.jad.2011.05.007
36 33 49. Yu X, Tam WW, Wong PT, et al. The Patient Health Questionnaire-9 for measuring
37 34 depressive symptoms among the general population in Hong Kong. *Comprehensive*
38 35 *psychiatry* 2012;53(1):95-102.
39 36 50. Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and
40 37 GAD-2: a systematic review and diagnostic metaanalysis. *General hospital psychiatry*
41 38 2016;39:24-31.
42 39 51. Leung GT, de Jong Gierveld J, Lam LC. Validation of the Chinese translation of the 6-item
43 40 De Jong Gierveld Loneliness Scale in elderly Chinese. *International psychogeriatrics*
44 41 2008;20(6):1262-72. doi: 10.1017/S1041610208007552
45 42 52. Doris S. Insomnia Severity Index: psychometric properties with Chinese
46 43 community-dwelling older people. *Journal of advanced nursing* 2010;66(10):2350-59.
47 44 53. Ngai SP, Cheung RT, Lam PL, et al. Validation and reliability of the Physical Activity Scale
48 45 for the Elderly in Chinese population. *Journal of rehabilitation medicine* 2012;44(5):462-
49 46 65.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 54. Rolfson DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton Frail
4 2 Scale. *Age and ageing* 2006;35(5):526-29.
5 3 55. Zhang D, Chan DC-C, Niu L, et al. Meaning and its association with happiness, health and
6 4 healthcare utilization: A cross-sectional study. *Journal of affective disorders*
7 5 2018;227:795-802.
8 6 56. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia.
9 7 *Journal of the American Medical Directors Association* 2013;14(8):531-32.
10 8 57. Woo J, Leung J, Morley JE. Validating the SARC-F: A suitable community screening tool
11 9 for sarcopenia? *Journal of the American Medical Directors Association* 2014;15(9):630-
12 10 34.
13 11 58. Wong A, Xiong YY, Kwan PW, et al. The validity, reliability and clinical utility of the Hong
14 12 Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel
15 13 disease. *Dementia and geriatric cognitive disorders* 2009;28(1):81-87.
16 14 59. Wong EL, Ramos-Goñi JM, Cheung AW, et al. Assessing the Use of a Feedback Module to
17 15 Model EQ-5D-5L Health States Values in Hong Kong. *The Patient-Patient-Centered*
18 16 *Outcomes Research* 2018;11(2):235-47.
19 17 60. Silva Junior SH, Santos SM, Coeli CM, et al. Assessment of participation bias in cohort
20 18 studies: systematic review and meta-regression analysis. *Cad Saude Publica*
21 19 2015;31(11):2259-74. doi: 10.1590/0102-311X00133814 [published Online First:
22 20 2016/02/04]
23 21 61. Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and
24 22 GAD-2: a systematic review and diagnostic metaanalysis. *General hospital psychiatry*
25 23 2016;39:24-31. doi: 10.1016/j.genhosppsych.2015.11.005 [published Online First:
26 24 2016/01/01]
27 25 62. Mitchell AJ, Yadegarfar M, Gill J, et al. Case finding and screening clinical utility of the
28 26 Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a
29 27 diagnostic meta-analysis of 40 studies. *BJPsych Open* 2016;2(2):127-38. doi:
30 28 10.1192/bjpo.bp.115.001685 [published Online First: 2016/10/06]
31 29
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Table 1 Core topic areas in questionnaires and examinations of the study

Assessment	Description
<i>Questionnaire</i>	
Use of medication	number and duration (0-1 year/2-5 years/>5 years) for antihypertensive, cardiovascular and hypolipidemic drugs, antidiabetics, antipsychotics and analgesics
Compliance of medication use	“At times, do you forget to take your prescription medications?” (no/yes)
Depression	The 2-item Patient Health Questionnaire (PHQ-2) for depression; The 9-item Patient Health Questionnaire (PHQ-9) for those with PHQ-2 \geq 3
Anxiety	The 2-item Generalised Anxiety Disorder (GAD-2); The 7-item Generalised Anxiety Disorder (GAD-7) for those with GAD-2 \geq 3
Loneliness*	De Jong Gierveld Loneliness Scale; and one question asking “Do you feel lonely? (Yes/No)” (added at a later stage)
Insomnia	The 7-item Insomnia Severity Index (ISI) for those answered yes to the screening question “In the past two weeks, do you have insomnia? (Yes/No)”
Pain	A screening question of “In the past year, do you have musculoskeletal pain for at least 3 months”, for those who answered ‘yes, one pain area or ‘yes, two or more pain areas’, Brief Pain Inventory (BPI) was measured.
Physical activity	For those were screened positive in pain, Physical Activity Scale for the Elderly (PASE) was measured
Self-rated health	“In general, how will you describe your health? (extremely good, very good or good/fair/poor)
Community network	“When you need help, do you have someone who is willing to and able to meet your needs?” (always/sometimes/never)
Meaning of existence*	One item extracted from the validated reliable Chinese Purpose in Life test (CPIL)
Use of social media	A screening question of “In the past two weeks, have you ever used the following social media”, for those who answered yes to any of the social media, they were further assessed with importance and comfort of using internet.
Oral health*	“Do you have any difficulty when biting or chewing foods (even with the use of denture)” (yes/no)
Incontinence*	“Do you have incontinence?” (yes/occasionally/no)
Frailty*	The Edmonton Frail Scale

Sarcopenia*	The 5-item Sarcopenia Assessment (SARC-F)
Cognition	Mainly assessed with Montreal Cognitive Assessment Hong Kong version (HK-MoCA) but in an earlier stage, Abbreviated Memory Inventory for Chinese (AMIC) was used.
Quality of life	The EuroQol EQ-5D-5L (EQ5D)
Daily Function	Instrumental Activities of Daily Living (IADL) including ability to use telephone, mode of transportation, shopping, food preparation, ability to handle finances
Use of health services	Visits to primary care doctors, specialist outpatient clinics, admission to hospital, use of services in elderly daycare centers and out-of-pocket healthcare cost both in private and public in the past year
Alcohol use	The 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C) for those who drank alcohol in the past year
Tobacco use	One question asking for current, ex- and non-smoking behavior
Caregiving to somebody else	“Are you taking care of somebody?” (Yes/No)
Social economic status	Age, gender, marriage, living status, employment, receiving of social welfare scheme
<u>Physical examination</u>	
Blood pressure	Measured twice in 15 minutes after rest
Body Mass Index (BMI)	
Waist circumference	
Handgrip strength	Each hand was measured twice
<u>Electronic health record and self-report data</u>	
Chronic diseases	43 common chronic conditions in 15 categories including: <ol style="list-style-type: none"> 1. Metabolic diseases (hypertension, lipid disorder, diabetes) 2. Cancer 3. Disease of the cardiovascular system (coronary heart disease, stroke/cerebrovascular disease, peripheral vascular disease) 4. Disease of the respiratory system (COPD, bronchiectasis, asthma, chronic pharyngitis /laryngitis) 5. Disease of the liver, spleen and gallbladder (gallbladder/spleen disease, viral hepatitis, chronic liver disease) 6. Disease of the stomach and intestines (dyspepsia and gastritis, diverticular disease of intestine, chronic enteritis; irritable bowel syndrome; constipation)

7. Disease of the musculoskeletal and connective tissue (chronic pain needing medication control, skeletal and connective tissue inflammation (such as arthritis, gout))
8. Disease of the genitourinary system (chronic kidney disease (nephritis), prostatitis, benign prostatic hyperplasia)
9. Disease of the ear, nose and throat (ENT) (chronic rhinitis, deafness/tinnitus)
10. Disease of the visual system (glaucoma/cataracts, blindness/amblyopia, diabetic eyes, retinal detachment)
11. Disease of the skin (eczema, psoriasis)
12. Disease of the blood (anemia)
13. Disease of the nervous system (multiple sclerosis, migraine, epilepsy, Parkinson's disease)
14. Mental disorders (schizophrenia/bipolar disorder, depression, anxiety & other stress related disorders, dementia)
15. Others

Use of medication

Medication use number and duration (0-1 year/2-5 years/>5 years) for antihypertensive drugs, cardiovascular drugs, cholesterol-lowering drugs, antidiabetics, antipsychotics and analgesics

* Measures were added at later stages: about 712 to 995 patients received these measures.

1
2
3

Table 2 Basic characteristics and biopsychosocial health profiles of the elderly with multimorbidity in primary care in Hong Kong

Characteristics	Un-weighted rates and analyses				Weighted rates and analyses			
	Female (n = 753)	Male (n = 324)	P values	Crude total %	Female (n = 568)	Male (n = 508)	P values	Weighted total %
Female				69.9%				52.8%
Age (mean, sd)	69.6 (6.6)	71.1 (7.1)	<0.001	70.0 (6.8)	71.3 (8.4)	70.2 (7.9)	0.097	70.5 (7.9)
60-64	22.8%	19.8%	0.002	22.0%	28.8%	31.4%		30.2%
65-69	35.6%	26.5%		32.9%	22.9%	25.3%		24.0%
70-74	21.8%	24.4%		22.5%	12.5%	14.5%		13.4%
75-79	9.7%	16.4%		11.6%	12.1%	13.0%		12.5%
80 or above	10.1%	13.0%		11.0%	23.8%	15.7%		20.0%
Marriage			<0.001				<0.001	
married	57.9%	89.2%		67.3%	54.7%	82.9%		68.1%
single/divorced/separated	11.8%	4.3%		9.6%	10.9%	9.6%		10.3%
widowed	30.2%	6.5%		23.1%	34.4%	7.5%		21.7%
No. of children (mean, sd)	2.5 (1.6)	2.5 (1.2)	0.409	2.52 (1.47)	2.7 (1.9)	2.4 (1.3)	0.013	2.53 (1.6)
Living alone	16.5%	8.3%	<0.001	14.0%	18.4%	11.9%	0.004	14.6%
Employment								
Retired/ Housewife	96.0%	82.4%	<0.001	91.9%	95.8%	77.5%	0.000	86.9%
Employed	4.0%	17.6%		8.1%	4.2%	22.5%		13.1%
Education (year, mean, sd)	7.2 (4.7)	8.7 (4.1)	<0.001	7.7 (4.6)	6.5 (4.6)	8.9 (4.1)	<0.001	7.7 (4.5)
Year of education \geq 6 years	46.8%	59.5%	0.001	49.3%	40.7%	63.2%	<0.001	51.8%
Social security recipient	58.1%	59.3%	0.726	58.6%	59.8%	50.5%	0.002	55.4%
Comprehensive Social Security Assistance (CSSA) Scheme	11.4%	7.1%	0.031	10.1%	12.3%	7.6%	0.011	10.1%
Fruit Voucher	44.7%	50.3%	0.089	46.4%	45.5%	41.5%	0.190	43.6%
Disability allowance	3.7%	3.1%	0.604	3.5%	3.9%	3.0%	0.426	3.5%
Other	0.5%	0.3%	0.621	0.5%	0.4%	0.3%	0.803	0.3%
Caregiving to somebody	18.9%	14.5%	0.118	17.6%	16.8%	13.0%	0.126	15.0%
Alcohol use								
Yes, in last 12 months	5.4%	29.3%	<0.001	12.6%	5.2%	29.8%	<0.001	16.8%
AUDIT-C [§]								
AUDIT-C positive (\geq 3)	1.4%	11.1%	<0.001	4.4%	1.5%	11.2%	<0.001	6.1%
Smoke			<0.001				<0.001	
Never smoke	97.1%	60.5%		86.1%	96.9%	60.3%		79.6%
Smoke	0.8%	7.1%		2.7%	0.8%	7.2%		3.8%
Quit smoke	2.1%	32.4%		11.2%	2.4%	32.5%		16.6%
Self-rated health							0.001	

1									
2									
3	Excellent/very good/good	26.0%	34.7%	<0.001	28.5%	26.8%	32.7%		29.5%
4	Fair	59.5%	58.4%		59.2%	58.6%	60.1%		59.3%
5	Poor	14.6%	6.9%		12.3%	14.7%	7.2%		11.2%
6	Number of chronic conditions (mean, sd)	4.0 (1.7)	4.3 (1.9)	0.004	4.1 (1.8)	4.0 (1.7)	4.3 (1.9)	0.026	4.1 (1.8)
7	2 diseases	21.4%	15.4%	0.003	19.6%	22.6%	16.0%	0.019	19.4%
8	3 diseases	25.5%	28.7%		26.5%	25.1%	29.8%		27.3%
9	4 diseases	21.0%	17.0%		19.8%	19.5%	16.1%		17.9%
10	5 disease	15.0%	13.0%		14.4%	14.8%	12.7%		13.8%
11	6+ disease	17.1%	25.9%		19.8%	18.1%	25.4%		21.5%
12	Chronic conditions by category								
13	Metabolic diseases	82.2%	86.7%	0.066	83.6%	83.8%	85.5%	0.449	84.6%
14	Cancer	7.3%	13.0%	0.003	9.0%	7.0%	11.6%	0.009	9.2%
15	Cardiovascular diseases (CVD)	13.4%	24.7%	<0.001	16.9%	14.5%	24.1%	<0.001	19.0%
16	Respiratory disease	6.1%	9.6%	0.043	7.2%	6.4%	9.9%	0.039	8.1%
17	Liver disease	9.3%	10.2%	0.649	9.6%	9.3%	10.8%	0.439	10.0%
18	Gastrointestinal disorders	28.0%	23.8%	0.148	26.7%	27.7%	23.2%	0.093	25.5%
19	Musculoskeletal disorders (MSK)	65.2%	48.8%	<0.001	60.3%	65.5%	49.8%	<0.001	58.1%
20	Thyroid disease	9.7%	1.9%	<0.001	7.3%	9.2%	1.9%	<0.001	5.7%
21	Renal disease	2.3%	33.3%	<0.000	11.6%	2.1%	31.7%	<0.001	16.1%
22	ENT	8.9%	9.3%	0.849	9.0%	8.8%	9.6%	0.645	9.2%
23	Eye	27.9%	22.5%	0.067	26.3%	29.1%	20.5%	0.001	25.0%
24	Skin	9.3%	9.9%	0.765	9.5%	9.0%	10.5%	0.401	9.7%
25	Anemia	3.1%	2.8%	0.806	3.0%	3.0%	2.8%	0.867	2.9%
26	Neurological disease	0.7%	1.2%	0.346	0.8%	0.5%	1.3%	0.175	0.9%
27	Mental disorders	16.7%	10.2%	0.005	14.8%	16.4%	11.2%	0.015	14.0%
28	Use of medication								
29	Antihypertensive drugs (mean, sd)	1.0 (0.9)	1.2 (0.9)	0.082	1.1 (0.9)	1.1 (0.9)	1.1 (0.9)	0.431	1.1 (0.9)
30	Percentage of patients who use	69.1%	75.3%	0.038	70.9%	71.3%	74.0%	0.326	72.5%
31	Cardiovascular drugs (mean, sd)	0.2 (0.5)	0.3 (0.6)	<0.001	0.2 (0.5)	0.2 (0.5)	0.3 (0.7)	0.024	0.24 (0.6)
32	Percentage of patients who use	11.8%	22.8%	<0.001	15.1%	12.7%	21.8%	<0.001	17.0%
33	Antidiabetics (mean, sd)	0.4 (0.7)	0.5 (0.8)	0.0195	0.4 (0.8)	0.3 (0.7)	0.5 (0.8)	0.029	0.4 (0.7)
34	Percentage of patients who use	22.6%	31.8%	0.001	25.4%	22.1%	31.9%	<0.001	26.7%
35	Cholesterol-lowering drugs (mean, sd)	0.4 (0.5)	0.5 (0.5)	0.005	0.4 (0.5)	0.4 (0.5)	0.5 (0.5)	0.004	0.4 (0.5)
36	Percentage of patients who use	38.8%	48.2%	0.004	41.6%	37.5%	48.4%	<0.001	42.7%
37	Antipsychotics (mean, sd)	0.2 (0.8)	0.1 (0.5)	0.038	0.2 (0.7)	0.2 (0.8)	0.1 (0.5)	0.035	0.2 (0.7)
38	Percentage of patients who use	11.7%	7.4%	0.035	10.4%	11.1%	7.7%	0.055	9.5%
39	Analgesics (mean, sd)	0.1 (0.5)	0.1(0.4)	0.875	0.1 (0.5)	0.1 (0.5)	0.1 (0.4)	0.929	0.1 (0.4)
40	Percentage of patients who use	10.5%	10.8%	0.879	10.6%	9.8%	10.2%	0.833	10.0%
41	Total number of medication (mean, sd)	2.3 (1.9)	2.7 (1.9)	0.001	2.4 (1.9)	2.3 (1.9)	2.6 (1.9)	0.025	2.5 (1.9)
42	% forgetting taking medication (n=995)	38.4%	34.0%	0.196	37.1%	36.3%	34.8%	0.640	35.6%
43	Oral Health Problem (n=992)	25.3%	20.6%	0.119	23.9%	24.8%	20.5%	0.104	22.8%
44	Incontinence (n=992)			0.004				<0.001	
45	No	77.0%	86.3%		79.7%	76.9%	86.6%		81.5%
46	Occasionally	21.3%	12.7%		18.8%	20.3%	12.7%		16.7%
47	Yes	1.7%	1.0%		1.5%	2.8%	0.7%		1.8%

Pain									
Muscle-skeletal pain for at least 3 months in the past year			0.000				<0.001		
	No	19.1%	37.7%		24.9%	18.7%	37.4%	27.5%	
	Yes, one pain area	19.7%	23.8%		10.9%	18.7%	23.6%	21.0%	
	Yes, two or more pain areas	61.2%	38.6%		64.3%	62.7%	39.0%	51.5%	
Brief Pain Inventory (BPI) ^c									
	Interference (n=809)	4.6 (1.9)	4.1 (1.9)	<0.001	4.5 (1.9)	4.7 (2.0)	4.1 (1.9)	<0.001	4.4 (2.0)
	Severity (n=810)	2.9 (2.2)	2.2 (1.8)	<0.001	2.7 (2.1)	2.9 (2.2)	2.2 (1.8)	<0.001	2.6 (2.1)
Physical Activity Scale for the Elderly (PASE) (n=809) ^d									
	Mean (SD)	77.4 (34.9)	89.1 (61.5)	<0.001	80.3 (43.4)	74.7 (36.1)	95.7 (67.3)	<0.001	83.3 (52.2)
Sarcopenia (mean, sd) (n=719) ^f									
	Positive (≥4)	11.0%	5.7%	0.019	9.3%	15.5%	5.1%	<0.001	10.4%
	Negative (0-3)	89.0%	94.3%		90.7%	84.5%	94.9%		89.6%
Cognition ^h									
	AMIC (mean, sd) (n=337)	2.2 (1.7)	1.7 (1.6)	0.035	2.1 (1.7)	2.1 (1.7)	1.6 (1.6)	0.038	1.9 (1.7)
	AMIC Positive % (≥3)	40.6%	27.3%	0.027	37.1%	39.3%	24.7%	0.007	33.3%
	HK-MOCA (n=785)	24.7 (4.3)	25.4 (3.2)	0.026	24.9 (4.0)	24.0 (4.8)	25.5 (3.1)	<0.001	24.7 (4.1)
	HK-MOCA Abnormal % (<22)	17.5%	12.6%	0.080	15.9%	23.0%	10.5%	<0.001	16.9%
Depression									
	PHQ-2	1.3 (1.6)	0.8 (1.2)	<0.001	1.2 (1.5)	1.3 (1.6)	0.8 (1.3)	<0.001	1.1 (1.5)
	Screen (-) (<3)	78.1%	88.3%	<0.001	81.2%	77.8%	87.6%	<0.001	82.4%
	Screen (+) (≥3)	21.9%	11.7%		18.9%	22.2%	12.4%		17.6%
	PHQ-9 (mean, sd) ^a	11.4 (4.3)	10.5 (4.5)	0.274	11.2 (4.4)	11.4 (4.2)	10.4 (4.3)	0.179	11.0 (4.3)
	Mild (5-9)	8.8%	4.3%		7.4%	8.6%	4.8%		6.8%
	Moderate (10-14)	7.3%	4.9%		6.6%	8.2%	5.4%		6.9%
	Moderately severe (15-19)	4.2%	1.2%		3.3%	4.0%	1.2%		2.7%
	Severe (20+)	1.3%	0.9%		1.2%	1.2%	0.8%		1.0%
Anxiety									
	GAD-2 (≥3) (mean, sd)	1.4 (1.5)	0.8 (1.1)	<0.001	1.2 (1.5)	1.4 (1.6)	0.8 (1.1)	<0.001	1.1 (1.4)
	Screen (-) (<3)	79.7%	91.1%	<0.001	83.0%	79.5%	90.9%	<0.001	84.9%
	Screen (+) (≥3)	20.3%	9.0%		17.0%	20.5%	9.1%		15.1%
	GAD-7 (mean, sd) ^b	10.8 (3.9)	9.8 (3.7)	0.182	10.7 (3.9)	10.9 (3.9)	10.1 (3.6)	0.294	10.7 (3.8)
	Mild (5-9)	0.9%	0.3%		0.7%	0.7%	0.2%		0.5%
	Moderate (10-14)	6.9%	4.6%		6.2%	8.5%	5.0%		6.8%
	Moderately Severe (15-19)	9.6%	3.4%		7.7%	10.1%	4.4%		7.4%
	Severe (20+)	2.9%	0.6%		2.2%	3.6%	0.6%		2.2%
Insomnia									
Insomnia in the past 2 weeks			0.030					0.086	
	No	31.5%	28.3%		33.5%	32.2%	37.2%	34.6%	
	Yes	68.5%	61.7%		66.5%	67.8%	62.8%	65.4%	

1									
2									
3	ISI (n=716) (mean, sd) ^e	12.0 (5.1)	10.2 (4.6)	<0.001	11.5 (5.0)	11.9 (5.1)	10.1 (4.5)	<0.001	11.1 (4.9)
4	No clinically significant insomnia (0-7)	13.7%	18.2%		15.0%	14.2%	18.8%		16.4%
5	Subthreshold insomnia (8-14)	31.1%	29.0%		30.5%	31.0%	29.7%		30.4%
6	Clinical insomnia, moderate severity (15-21)	22.2%	14.2%		19.8%	22.1%	15.0%		18.8%
7	Clinical insomnia, severe (22-28)	1.6%	0.3%		1.2%	1.5%	0.3%		0.9%
8	Meaning (0-7) (n=544)	4.8 (1.2)	5.0 (1.1)	0.098	4.8 (1.2)	4.7 (1.3)	5.0 (1.1)	0.022	4.9 (1.2)
9	Loneliness (n=741)								
10	One question (yes/no)			0.009				0.128	
11	No	68.0%	77.1%		72.5%	69.8%	74.6%		72.2%
12	Yes	32.1%	22.9%		27.5%	30.2%	25.4%		27.9%
13	De Jong Gierveld Loneliness Scale								
14	Total loneliness score (mean, sd)	1.8 (1.9)	1.6 (1.7)	0.121	0.7 (1.2)	1.8 (1.8)	1.6 (1.7)	0.309	1.7 (1.8)
15	Emotional loneliness score (mean, sd)	1.0 (1.1)	0.9 (1.0)	0.156	1.6 (1.8)	0.9 (1.0)	0.9 (1.0)	0.566	0.9 (1.0)
16	Social loneliness score (mean, sd)	0.8 (1.3)	0.7 (1.2)	0.121	0.9 (1.0)	0.8 (1.3)	0.7 (1.3)	0.350	0.8 (1.3)
17	Social Support (can count on someone willing and able to meet your needs)			0.083				0.146	
18	Always	61.2%	66.3%		62.7%	61.6%	65.8%		63.5%
19	Sometimes	31.1%	30.0%		30.7%	31.2%	28.6%		30.0%
20	Never	7.7%	4.1%		6.7%	7.3%	5.6%		6.5%
21	Use of social media in last 2 weeks								
22	Yes	52.5%	52.1%	0.849	52.6%	46.6%	55.8%	0.003	51.0%
23	Web	20.9%	33.6%	<0.001	24.7%	18.5%	36.5%	<0.001	27.0%
24	WhatsApp	51.4%	50.0%	0.675	51.0%	45.9%	52.6%	0.028	49.0%
25	Facebook	15.9%	20.4%	0.077	17.3%	14.5%	20.7%	0.006	17.4%
26	Blog	1.7%	3.4%	0.089	2.2%	1.3%	3.0%	0.065	2.1%
27	E-literacy (n=566) ^e	25.0 (11.7)	24.9 (12.6)	0.931	25.0 (12.0)	25.5 (11.6)	25.4 (12.7)	0.953	25.4 (12.2)
28	Importance of social media (total score: 6-24)	11.3 (4.8)	10.8 (4.7)	0.218	11.1 (4.8)	11.5 (4.7)	10.8 (4.8)	0.171	11.1 (4.8)
29	Comfort of using social media (total score: 3-18)	8.2 (4.5)	8.2 (4.7)	0.975	8.2 (4.5)	8.3 (4.4)	8.3 (4.7)	0.878	8.3 (4.5)
30	Daily function (Percentage of patients needing help or being dependent)								
31	Total	8.4%	14.8%	0.001	10.3%	10%	14.3%	0.056	12.3%
32	Using telephone	0.7%	1.2%		0.8%	1%	1%		1%
33	Transportation	4.7%	5.6%		4.3%	5.9%	5.4%		5.7%
34	Shopping	5.7%	5.0%		5.5%	7.5%	4.8%		6.2%
35	Preparing meals	4.3%	12.7%		6.8%	5.5%	12.7%		8.9%
36	Financial management	2.9%	4.9%		3.5%	4.1%	0.9%		2.6%
37	Frailty								
38	Edmonton Frail Scale (EFS) (mean, sd) (n=989) ^f	3.5 (2.3)	3.1 (2.0)	0.003	3.4 (2.2)	3.7 (2.4)	3.1 (2.0)	<0.001	3.4 (2.2)
39	No frailty (0-5)	80.3%	88.3%	0.012	82.6%	77.6%	88.7%	<0.001	82.8%
40	Apparently vulnerable (6-7)	13.7%	8.6%		12.2%	13.8%	8.7%		11.4%
41	Mild frailty (8-9)	4.7%	2.4%		4.0%	6.8%	2.0%		4.6%
42	Moderate frailty (10-11)	1.3%	0.3%		1.0%	1.8%	0.2%		1.1%

Severe frailty (12-18)	0%	0.33%		0.1%		0%	0.4%		0.2%
Quality of life (EQ5D-5L)									
Index score (range: -0.864 to 1)	0.8 (0.2)	0.9 (0.2)	0.001	0.81 (0.20)		0.8 (0.2)	0.9 (0.2)	<0.001	0.81 (0.2)
visual analogue scale (VAS) (0-100)	66.0 (15.3)	69.6 (13.4)	<0.001	67.1 (14.8)		66.0 (15.4)	69.4 (13.3)	0.001	67.6 (14.6)
Health care utilization in the past year									
Hospitalization frequency									
			0.453					0.557	
0	83.8%	81.2%		83.0%		83.6%	82.0%		82.9%
1-2	14.4%	17.3%		15.2%		14.0%	16.7%		15.3%
2+	1.9%	1.5%		1.8%		2.4%	1.3%		1.9%
Hospitalization Length (days, mean, sd) (n=1073)	1.1 (5.1)	1.5 (8.2)	0.424	1.2 (6.2)		1.1 (5.1)	1.4 (8.3)	0.535	1.2 (6.8)
Specialist Out-patient Clinics (SOPC)	69.0%	70.7%	0.587	69.5%		68.8%	70.2%	0.636	69.5%
General Out-patient Clinics (GOPC)	89.6%	94.1%	0.018	91.0%		89.8%	94.3%	0.007	92.0%
Elderly day care service	9.4%	9.9%	0.824	9.6%		10.2%	9.1%	0.554	9.6%
Cost (out of pocket) (HKD) median (interquartile range, IQR) (n=1063)	1000 (0, 3000)	1000 (0, 2000)	0.141	1000 (0, 3000)		1000 (0, 3000)	1000 (0, 2000)	0.488	1000 (0, 3000)
Physical examinations									
Blood pressure (BP)									
Systolic (mean, sd)	133.2 (15.6)	134.2 (15.9)	0.337	133.5 (15.7)		133.5 (16.3)	133.3 (15.2)	0.848	133.4 (15.8)
Diastolic (mean, sd)	74.9 (9.6)	78.4 (10.0)	<0.001	75.9 (9.9)		74.1 (10.0)	78.6 (9.9)	<0.001	76.2 (10.2)
Normal (SBP <120 & DBP <80)	19.2%	14.8%	0.272	17.9%		19.9%	15.8%	0.070	17.9%
Pre-hypertension (SBP: 120-139 or DBP: 80-89)	45.8%	48.2%		46.5%		44.6%	48.4%		46.4%
Stage I hypertension (SBP: 140-159 or DBP: 90-99)	30.2%	30.6%		30.3%		29.9%	29.8%		29.8%
Stage II hypertension (SBP ≥ 160 or DBP ≥ 100)	4.8%	6.5%		5.3%		5.6%	6.0%		5.8%
Pulse (per minute)	71.5 (19.5)	75.2 (28.0)	0.016	72.7 (22.5)		71.7 (22.0)	74.9 (24.8)	0.041	73.2 (23.4)
Weight (kg, mean, sd)	57.5 (56.8)	66.5 (9.6)	<0.001	60.2 (10.4)		56.9 (9.3)	66.9 (9.7)	<0.001	61.6 (10.7)
Height (cm, mean, sd)	154.0 (6.2)	165.5 (6.7)	<0.001	157.4 (8.2)		153.4 (6.2)	165.6 (6.7)	<0.001	159.2 (8.8)
Waist circumference (cm, mean, sd)	88.8 (9.7)	93.2 (9.5)	<0.001	90.2 (9.9)		89.1 (9.9)	93.2 (9.2)	<0.001	91.1 (9.8)
Body mass Index (BMI) (mean, sd)	24.2 (3.8)	24.2 (2.0)	0.963	24.2 (3.6)		24.2 (3.7)	24.4 (3.1)	0.398	24.3 (3.4)
Underweight (<18.5)	4.1%	2.8%	0.067	3.7%		3.6%	2.7%	0.013	3.1%
Normal (18.5-22.9)	37.6%	31.3%		35.7%		38.9%	31.5%		35.4%
Overweight (23-24.9)	20.4%	26.0%		22.1%		20.5%	23.6%		22.0%
Obese (≥ 25)	37.9%	39.9%		38.5%		37.0%	42.2%		39.5%
Handgrip strength (kg) ⁱ									
< cutoff score (<26 for male, <18 for female)	36.3%	36.1%	0.964	36.2%		40.2%	34.7%	0.061	37.6%

Left hand (mean, sd)	17.4 (4.2)	26.4 (7.0)	20.1 (6.6)	17.0 (4.2)	26.7 (7.0)	21.5 (7.5)
Right hand (mean, sd)	18.5 (4.3)	27.4 (7.5)	21.1 (6.8)	18.0 (4.3)	27.5 (7.7)	22.5 (7.7)
Both hand (mean, sd)	19.1 (4.1)	28.5 (7.1)	21.9 (6.7)	18.6 (4.0)	28.8 (7.2)	23.4 (7.6)

Abbreviations: GAD-2: the two-item General Anxiety Disorder scale; HK-MoCA: Montreal Cognitive Assessment Hong Kong version (HK-MoCA); ISI: the 7-item Insomnia Severity Index; EQ5D: the EuroQol EQ-5D-5L; PHQ-2: The two item Patient Health Questionnaire for depression; The 3-item Alcohol Use Disorders Identification Test-consumption (AUDIT-C); SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure.

Statistical methods: Chi square tests were used for categorical data; paired t tests were used for continuous data.

Notes:

^a Mean (SD) was for 203 patients who did PHQ-9. The % was for all the 1077 patients with the rest 874 patients who screened negative in PHQ-2 regarded as having normal scores in PHQ-9.

^b Mean (SD) was for 182 patients who did GAD-7. The % was for all the 1077 patients with the rest 895 patients who screened negative in GAD-2 regarded as having normal scores in GAD-7.

^c 719 patients were assessed with ISI.

^d Only those who had one or more pain areas in the past 3 months were assessed with BPI or PASE-C.

^e Only those who had social media use in the past 2 weeks were assessed.

^f Measured by the 5-item Sarcopenia Assessment (SARC-F) which were added at a later stage.

^g N=136, those who did not drink alcohol the past 12 months were regarded as 0 in AUDIT-C.

^h HK-MOCA replaced AMIC in a later stage.

ⁱ Better result of two series for left or right hand, or best result of both hands.

1
2
3
4
5 Figure 1 Flowchart of recruitment
6
7
8
9
10

11
12 Figure 2 Unweighted prevalence of co-morbidities (by 15 disease categories) among the 1077
13 elderly with multimorbidity
14

15 (Figures are unweighted (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK:
16 Musculoskeletal Disorders; ENT: eye, nose and throat)
17
18

19
20 Figure 3 Weighted prevalence of co-morbidities (by 15 disease categories) among the 1077
21 elderly with multimorbidity
22

23 (Figures are weighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK:
24 Musculoskeletal Disorders; ENT: eye, nose and throat)
25
26
27
28
29
30

31 Figure 4 Unweighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43
32 specific chronic conditions) among the 1077 elderly with multimorbidity
33

34 (Figures are unweighted prevalence (%))
35
36
37

38 Figure 5 Weighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43
39 specific chronic conditions) among the 1077 elderly with multimorbidity
40

41 (Figures are weighted prevalence (%))
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flowchart of recruitment




Figure 2 Unweighted prevalence of co-morbidities (by 15 disease categories) among the 1077 elderly with multimorbidity

(Figures are unweighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK: Musculoskeletal Disorders; ENT: eye, nose and throat)




Figure 3 Weighted prevalence of co-morbidities (by 15 disease categories) among the 1077 elderly with multimorbidity

(Figures are weighted prevalence (%); CVD: cardiovascular disease; GI disease: gastrointestinal disease; MSK: Musculoskeletal Disorders; ENT: eye, nose and throat)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 4 Unweighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43 specific chronic conditions) among the 1077 elderly with multimorbidity (Figures are unweighted prevalence (%))




Figure 5 Weighted prevalence of the co-morbidities of top 10 chronic conditions (out of 43 specific chronic conditions) among the 1077 elderly with multimorbidity (Figures are weighted prevalence (%))

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	P1-2	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4–5	
Objectives	3	State specific objectives, including any prespecified hypotheses	P5	
Methods				
Study design	4	Present key elements of study design early in the paper	P5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5-8	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P5-8	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P6-8, Table 1	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P6-8, Table 1	
Bias	9	Describe any efforts to address potential sources of bias	P8-9	
Study size	10	Explain how the study size was arrived at	P6	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P9-10, Table 2
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8-10
		(b) Indicate number of participants with missing data for each variable of interest	P8-10, Table 2, Figure 2, Figure 3
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	P9-10, Table 2, Figure 2, Figure 3
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	Table 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period NA

Continued on next page

For peer review only

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA	
Discussion				
Key results	18	Summarise key results with reference to study objectives	p11	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p13-14	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p12-13	
Generalisability	21	Discuss the generalisability (external validity) of the study results	p14	
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p1	Funding The work was supported by The Hong Kong Jockey Club Charities Trust.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.